IRF4

Existing Annotations Review

GO Term	Evidence	Action	Reason
GO:0002376 immune system process	IBA GO_REF:0000033	ACCEPT	Summary: IRF4 is a lymphoid-restricted transcription factor that plays critical roles across multiple arms of the immune system, including B cell differentiation to plasma cells, T helper cell lineage commitment (Th2, Th9, Th17), effector CD8+ T cell differentiation, and dendritic cell and macrophage programs (PMID:12374808, deep research review). Reason: This broad IBA annotation is accurate. IRF4 is expressed almost exclusively in immune cells and its functions are overwhelmingly immunological. The IBA is supported by phylogenetic inference across the IRF family and is consistent with extensive experimental evidence for IRF4 roles in both adaptive and innate immunity. Supporting Evidence: PMID:12374808 Interferon regulatory factor (IRF)-4 is a lymphoid-restricted member of the interferon regulatory factor family of transcriptional regulators, whose deficiency leads to a profound impairment in the ability of mature CD4(+) T cells to produce cytokines.
GO:0005634 nucleus	IBA GO_REF:0000033	ACCEPT	Summary: IRF4 is a transcription factor that functions in the nucleus, where it binds DNA at ISRE, EICE, and AICE composite elements to regulate target gene transcription. Nuclear localization is confirmed by UniProt annotation (ECO:0000269\|PubMed:36917008) and structural studies of the DBD. Reason: Nuclear localization is a core feature of IRF4 function as a DNA-binding transcription factor. The IBA annotation is consistent with multiple experimental lines of evidence including immunofluorescence and functional characterization of disease-causing variants that alter nuclear partitioning. Supporting Evidence: PMID:36917008 Here, based on our investigation of a multigeneration family, we describe a novel autosomal dominant PAD caused by a pathogenic IRF4 variant affecting the IAD. All three patients in the family presented with low IgM, IgG, and IgA serum levels (diagnosed during childhood); low plasma cell counts; abnormal T cell subsets; and early hair graying.
GO:0006357 regulation of transcription by RNA polymerase II	IBA GO_REF:0000033	ACCEPT	Summary: IRF4 is a DNA-binding transcription factor that regulates RNA polymerase II transcription of target genes including cytokines (IL-2, IL-4, IL-10, IL-13, IL-17), immunoglobulin genes, and genes involved in lymphocyte differentiation programs. It transactivates luciferase reporters driven by IL-2 and IL-4 promoters (PMID:12374808). Reason: Regulation of Pol II transcription is the core biological process in which IRF4 participates. The IBA annotation is well-supported by the phylogeny of the IRF family and extensive experimental data from reporter assays, ChIP-seq, and genetic studies. Supporting Evidence: PMID:12374808 Transient transfection assays indicate that IRF-4 can transactivate luciferase reporter constructs driven by either the human IL-2 or the human IL-4 promoter.
GO:0000981 DNA-binding transcription factor activity, RNA polymerase II-specific	IBA GO_REF:0000033	ACCEPT	Summary: IRF4 is a sequence-specific DNA-binding transcription factor that regulates RNA polymerase II-dependent transcription. It binds ISRE motifs and composite elements (EICE, AICE) with partner TFs to activate target gene transcription. This is supported by crystal structures of the DBD bound to DNA, reporter assays, and ChIP-seq data. Reason: This is the core molecular function of IRF4. The IBA annotation is consistent with extensive experimental evidence showing IRF4 functions as a DNA-binding transcription factor. Per GO-CAM TF annotation guidelines, this is the appropriate parent term for transcription factor activity. Supporting Evidence: PMID:12374808 Transient transfection assays indicate that IRF-4 can transactivate luciferase reporter constructs driven by either the human IL-2 or the human IL-4 promoter. PMID:28473536 By analysis of 542 human TFs with methylation-sensitive SELEX (systematic evolution of ligands by exponential enrichment), we found that there are also many TFs that prefer CpG-methylated sequences.
GO:0000978 RNA polymerase II cis-regulatory region sequence-specific DNA binding	IBA GO_REF:0000033	ACCEPT	Summary: IRF4 binds sequence-specifically to cis-regulatory regions of Pol II-transcribed target genes, including ISRE motifs in MHC class I promoter, the immunoglobulin lambda light chain enhancer (with PU.1), and promoter regions of cytokine genes (IL-2, IL-4). The IRF4 DBD recognizes GAAA core motifs. Reason: This accurately captures IRF4's DNA-binding specificity at cis-regulatory regions. The IBA annotation is supported by direct evidence from EMSA, reporter assays, and ChIP-seq studies. IRF4 binds cis-regulatory elements in a sequence-specific manner, recognizing ISRE, EICE, and AICE motifs. Supporting Evidence: PMID:12374808 A detailed analysis of the effects of IRF-4 on the IL-4 promoter reveals that IRF-4 binds to a site adjacent to a functionally important NFAT binding element and that IRF-4 cooperates with NFATc1.
GO:0000976 transcription cis-regulatory region binding	IEA GO_REF:0000002	ACCEPT	Summary: Electronic annotation based on InterPro domain IPR001346 (IRF DNA-binding domain). IRF4 does bind cis-regulatory regions through its conserved tryptophan pentad repeat DBD. Reason: This IEA annotation is accurate but less specific than the IBA annotation for GO:0000978. The InterPro-based mapping correctly identifies cis-regulatory region binding as a function of the IRF DNA-binding domain. It is acceptable as a broader parent of the more specific IBA terms.
GO:0000978 RNA polymerase II cis-regulatory region sequence-specific DNA binding	IEA GO_REF:0000117	ACCEPT	Summary: ARBA machine learning annotation for Pol II cis-regulatory region binding. Consistent with both the IBA annotation and direct experimental evidence. Reason: This IEA annotation is a duplicate of the IBA annotation at GO:0000978 and is correct. The ARBA-based electronic annotation independently supports the same molecular function.
GO:0003677 DNA binding	IEA GO_REF:0000043	MODIFY	Summary: General DNA binding annotation from UniProt keyword mapping. IRF4 does bind DNA through its N-terminal tryptophan pentad repeat domain (aa 21-129). Reason: While IRF4 unquestionably binds DNA, this term is too general and uninformative. More specific terms such as GO:0000978 (RNA polymerase II cis-regulatory region sequence-specific DNA binding) or GO:1990837 (sequence-specific double-stranded DNA binding) better capture IRF4's function. Proposed replacements: RNA polymerase II cis-regulatory region sequence-specific DNA binding
GO:0003700 DNA-binding transcription factor activity	IEA GO_REF:0000120	ACCEPT	Summary: Combined automated annotation for DNA-binding transcription factor activity. Consistent with experimental evidence and more specific IBA/IDA annotations. Reason: This is a correct annotation. While the more specific child term GO:0000981 (RNA polymerase II-specific) is also annotated, this broader parent term from automated methods is not wrong and is acceptable as a general descriptor.
GO:0005634 nucleus	IEA GO_REF:0000044	ACCEPT	Summary: Electronic annotation for nuclear localization based on UniProt subcellular location vocabulary. Consistent with IRF4 being a nuclear transcription factor. Reason: Correct annotation. IRF4 is primarily nuclear, consistent with its function as a DNA-binding transcription factor. This is supported by both IBA and IMP annotations at the same term.
GO:0005737 cytoplasm	IEA GO_REF:0000044	ACCEPT	Summary: Electronic annotation for cytoplasmic localization based on UniProt subcellular location. UniProt reports cytoplasmic localization based on PMID:36917008. Reason: IRF4 is found in both nucleus and cytoplasm. The cytoplasmic pool likely represents either newly synthesized protein prior to nuclear import or a regulated cytoplasmic retention mechanism. This is consistent with the IMP annotation at the same term from PMID:36917008.
GO:0006355 regulation of DNA-templated transcription	IEA GO_REF:0000002	ACCEPT	Summary: InterPro-based annotation for regulation of DNA-templated transcription, based on IRF domains IPR019471 and IPR019817. Reason: This is a correct but general annotation. IRF4 is a transcription factor and regulation of DNA-templated transcription is its core biological process. While more specific terms exist (e.g., GO:0006357 regulation of transcription by RNA polymerase II), this broader IEA annotation from InterPro mapping is not wrong.
GO:0045944 positive regulation of transcription by RNA polymerase II	IEA GO_REF:0000117	ACCEPT	Summary: ARBA machine learning annotation for positive regulation of Pol II transcription. IRF4 primarily acts as a transcriptional activator. Reason: This is correct and consistent with the IDA annotation at the same term (PMID:12374808). IRF4 functions predominantly as a transcriptional activator, demonstrated by reporter assays showing transactivation of IL-2 and IL-4 promoter constructs.
GO:0051240 positive regulation of multicellular organismal process	IEA GO_REF:0000117	MARK AS OVER ANNOTATED	Summary: ARBA-based annotation for positive regulation of multicellular organismal process. Reason: This term is extremely broad and uninformative. While IRF4 does participate in processes that positively regulate multicellular organismal processes (e.g., immune cell differentiation), this annotation is too vague to be useful. More specific terms like regulation of T-helper cell differentiation or plasma cell differentiation are far more informative.
GO:0005515 protein binding	IPI PMID:21903422 Mapping a dynamic innate immunity protein interaction networ...	MARK AS OVER ANNOTATED	Summary: This annotation derives from a large-scale innate immunity interactome study (HI5) that mapped protein interactions regulating type I interferon production. IRF4 (as bait or prey) was found to interact with IKBKAP (ELP1), IRAK1, TLK2, and YTHDC2 by affinity purification-mass spectrometry (PMID:21903422). The paper notes IKBKAP interacts with IRF4 and negatively regulates HSV-induced IFN production. Reason: While the physical interactions detected in this high-throughput screen are plausible, generic "protein binding" is uninformative. Some of these interactions (e.g., with ELP1/IKBKAP) are from a large-scale screen and may not reflect core IRF4 biology. The functionally important interactions of IRF4 are with PU.1/SPI1, BATF/JUN, SPIB, and DEF6, which are better described by more specific binding terms. Supporting Evidence: PMID:21903422 IKBKAP interacts with IRF4 and negatively regulates HSV-induced IFN production.
GO:0005515 protein binding	IPI PMID:32296183 A reference map of the human binary protein interactome.	MARK AS OVER ANNOTATED	Summary: This annotation derives from the HuRI (Human Reference Interactome) project, a systematic binary interactome mapping using yeast two-hybrid. IRF4 interactions with GIPC2 and TSEN54 were detected. Reason: Generic "protein binding" from a high-throughput yeast two-hybrid screen is uninformative. The detected interactions (GIPC2, TSEN54) do not have clear functional relevance to IRF4's known biology as a transcription factor in immune cells. These may represent technical artifacts or biologically minor interactions. Supporting Evidence: PMID:32296183 Here we present a human 'all-by-all' reference interactome map of human binary protein interactions, or 'HuRI'. With approximately 53,000 protein-protein interactions, HuRI has approximately four times as many such interactions as there are high-quality curated interactions from small-scale studies.
GO:0000786 nucleosome	IEA GO_REF:0000107	MARK AS OVER ANNOTATED	Summary: Ensembl Compara-transferred annotation from mouse IRF4 (Q64287) suggesting IRF4 is part of nucleosomes. Reason: While IRF4 binds chromatin and may interact with nucleosomal DNA in the context of chromatin remodeling, being annotated as "part_of nucleosome" is misleading. IRF4 is not a histone or structural component of the nucleosome. It is a transcription factor that binds to cis-regulatory elements, some of which may be nucleosomal. The chromatin (GO:0000785) annotation is more appropriate.
GO:0000987 cis-regulatory region sequence-specific DNA binding	IEA GO_REF:0000107	ACCEPT	Summary: Ensembl Compara-transferred annotation from mouse IRF4 for cis-regulatory region sequence-specific DNA binding. Reason: This is correct and consistent with other annotations. IRF4 binds cis-regulatory regions in a sequence-specific manner at ISRE, EICE, and AICE motifs. This is a parent term of GO:0000978 which is also annotated.
GO:0003713 transcription coactivator activity	IEA GO_REF:0000107	MODIFY	Summary: Ensembl Compara-transferred annotation suggesting IRF4 has transcription coactivator activity, based on mouse ortholog data. Reason: IRF4 is primarily a DNA-binding transcription factor, not a coactivator. A coactivator does not directly bind DNA but enhances transcription through interaction with DNA-binding TFs. IRF4 directly binds DNA at ISRE/EICE/AICE elements. The appropriate term is GO:0001228 (DNA-binding transcription activator activity, RNA polymerase II-specific), which is already annotated with experimental evidence. This annotation likely derives from mouse studies where IRF4 cooperates with other TFs, but cooperation does not make it a coactivator. Proposed replacements: DNA-binding transcription activator activity, RNA polymerase II-specific
GO:0042832 defense response to protozoan	IEA GO_REF:0000107	KEEP AS NON CORE	Summary: Ensembl Compara-transferred annotation from mouse IRF4 for defense response to protozoan. Mouse Irf4 is required for immune defense against Leishmania and Toxoplasma. Reason: While IRF4 is required for effective immune responses including those against protozoan parasites (primarily through its role in T cell differentiation and cytokine regulation), defense response to protozoan is not a core function of IRF4. It is a downstream consequence of IRF4's role in immune cell differentiation. The annotation is based on mouse ortholog data where IRF4 knockout mice show susceptibility to protozoan infection.
GO:0043565 sequence-specific DNA binding	IEA GO_REF:0000107	ACCEPT	Summary: Ensembl Compara-transferred annotation for sequence-specific DNA binding from mouse IRF4. Reason: This is correct. IRF4 binds DNA in a sequence-specific manner through its tryptophan pentad repeat DBD, recognizing GAAA core motifs. This is a parent term of the more specific cis-regulatory region binding terms also annotated.
GO:0045893 positive regulation of DNA-templated transcription	IEA GO_REF:0000107	ACCEPT	Summary: Ensembl Compara-transferred annotation for positive regulation of DNA-templated transcription. Reason: Correct and consistent with the IDA annotation at the same term from PMID:12374808. IRF4 functions primarily as a transcriptional activator, as demonstrated by reporter assays with IL-2 and IL-4 promoter constructs.
GO:0072540 T-helper 17 cell lineage commitment	IEA GO_REF:0000107	KEEP AS NON CORE	Summary: Ensembl Compara-transferred annotation from mouse IRF4 for Th17 cell lineage commitment. Mouse studies show IRF4 is required for Th17 differentiation, binding and promoting Il17a/f, Il21, and Rorc expression. Reason: IRF4 is indeed essential for Th17 differentiation in mouse, and this role is conserved in human. However, Th17 lineage commitment is one of several immune cell differentiation programs regulated by IRF4 (also Th2, Th9, effector CD8+, plasma cells). This is a legitimate but non-core annotation representing one specific downstream function. The annotation is based on transfer from well-established mouse experimental data.
GO:0120162 positive regulation of cold-induced thermogenesis	IEA GO_REF:0000107	KEEP AS NON CORE	Summary: Ensembl Compara-transferred annotation from mouse IRF4 for positive regulation of cold-induced thermogenesis. This derives from a mouse study (PMID:24995979) showing IRF4 promotes thermogenic gene expression in brown adipose tissue. Reason: This annotation reflects a non-immune role of IRF4 in thermogenesis/adipose biology. While interesting, this is clearly a non-core function given that IRF4 is predominantly expressed in and functionally characterized in lymphoid cells. The human relevance of this mouse finding is uncertain.
GO:0005654 nucleoplasm	IDA GO_REF:0000052	ACCEPT	Summary: IDA annotation based on immunofluorescence data curated by the Human Protein Atlas (HPA). IRF4 is detected in the nucleoplasm by immunofluorescence in relevant cell types. Reason: Nucleoplasm localization is expected and correct for a transcription factor. The IDA evidence from immunofluorescence is reliable for localization. IRF4 functions in the nucleoplasm where it binds DNA and regulates transcription.
GO:0001228 DNA-binding transcription activator activity, RNA polymerase II-specific	IMP PMID:36662884 A multimorphic mutation in IRF4 causes human autosomal domin...	ACCEPT	Summary: IMP annotation based on Fornes et al. (2023) Sci Immunol, which characterized IRF4 T95R variant in IMD131 patients. The T95R mutant gains neomorphic DNA binding to GATA-containing sequences not recognized by wildtype, while showing decreased transcription activation from canonical ISRE reporter constructs. This demonstrates that wildtype IRF4 normally has DNA-binding transcription activator activity. Reason: The mutant phenotype analysis confirms that wildtype IRF4 functions as a DNA-binding transcription activator. Loss of this activity in disease-causing variants directly supports the annotation. This is the most specific appropriate MF term per GO-CAM TF guidelines. Supporting Evidence: PMID:36662884 Interferon regulatory factor 4 (IRF4) is a transcription factor (TF) and key regulator of immune cell development and function. We report a recurrent heterozygous mutation in IRF4, p.T95R, causing an autosomal dominant combined immunodeficiency (CID) in seven patients from six unrelated families.
GO:0001228 DNA-binding transcription activator activity, RNA polymerase II-specific	IMP PMID:36917008 A neomorphic mutation in the interferon activation domain of...	ACCEPT	Summary: IMP annotation based on Thouenon et al. (2023) J Exp Med, characterizing the IRF4 F359L neomorphic variant in IMD131 patients. The F359L variant shows loss of DNA-binding transcription activator activity, confirming this is the normal function of wildtype IRF4. Reason: Another disease variant study that confirms IRF4's transcriptional activator function through loss-of-function analysis. The F359L mutation in the IAD abolishes activator activity. Supporting Evidence: PMID:36917008 The mutant IRF4 failed to efficiently regulate the transcriptional activity of interferon-stimulated response elements (ISREs). Rapid immunoprecipitation mass spectrometry of endogenous proteins indicated that the mutant and wildtype IRF4 proteins differed with regard to their respective sets of binding partners.
GO:0005634 nucleus	IMP PMID:36917008 A neomorphic mutation in the interferon activation domain of...	ACCEPT	Summary: IMP annotation for nuclear localization from the Thouenon et al. (2023) study. The F359L variant shows no effect on subcellular location, indicating that wildtype (and mutant) IRF4 localizes to the nucleus. Reason: Nuclear localization is well-established for IRF4 and confirmed by this IMP study. This is expected for a DNA-binding transcription factor. Supporting Evidence: PMID:36917008 The IRF4 F359L and IRF4 WT proteins were similar with regard to their subcellular localization in the cytoplasm and the nucleus
GO:0005737 cytoplasm	IMP PMID:36917008 A neomorphic mutation in the interferon activation domain of...	ACCEPT	Summary: IMP annotation for cytoplasmic localization from the Thouenon et al. (2023) study. IRF4 is present in cytoplasm as well as nucleus. Reason: Cytoplasmic localization is confirmed by experimental evidence. IRF4 is likely present in the cytoplasm as a pre-nuclear pool or under conditions of cytoplasmic retention. This is consistent with UniProt subcellular localization annotation. Supporting Evidence: PMID:36917008 The IRF4 F359L and IRF4 WT proteins were similar with regard to their subcellular localization in the cytoplasm and the nucleus
GO:0001228 DNA-binding transcription activator activity, RNA polymerase II-specific	IMP PMID:29537367 IRF4 haploinsufficiency in a family with Whipple's disease.	ACCEPT	Summary: IMP annotation from Guerin et al. (2018) eLife, characterizing the IRF4 R98W variant in a family with Whipple's disease and IRF4 haploinsufficiency. The R98W mutation causes loss of DNA-binding transcription activator activity, and RC98-99AA double mutant also loses this activity. Reason: The loss-of-function analysis of the R98W disease variant provides direct evidence that wildtype IRF4 has DNA-binding transcription activator activity. The R98 residue is within the IRF DBD (aa 21-129) and is critical for DNA contact. Supporting Evidence: PMID:29537367 We found that R98W was loss-of-function, modified the transcriptome of heterozygous leukocytes following Tw stimulation, and was not dominant-negative. We also found that only six of the other 153 known non-synonymous IRF4 variants were loss-of-function.
GO:0005654 nucleoplasm	TAS Reactome:R-HSA-9907145	ACCEPT	Summary: TAS annotation from Reactome pathway R-HSA-9907145 (IRF4 binds the TYR promoter), placing IRF4 in the nucleoplasm where it binds the tyrosinase promoter in cooperation with MITF. Reason: Correct localization for a transcription factor binding a target promoter. The Reactome pathway describes IRF4's role in pigmentation gene regulation.
GO:0005654 nucleoplasm	TAS Reactome:R-HSA-9907147	ACCEPT	Summary: TAS annotation from Reactome pathway R-HSA-9907147 (MITF-M-dependent IRF4 gene expression), placing IRF4 in the nucleoplasm. Reason: Correct annotation. IRF4 is expressed and functions in the nucleoplasm.
GO:0005515 protein binding	IPI PMID:33951726 Constrained chromatin accessibility in PU.1-mutated agammagl...	MODIFY	Summary: IPI annotation from Le Coz et al. (2021) J Exp Med, demonstrating that IRF4 directly interacts with PU.1 (SPI1). PU.1 mutations in agammaglobulinemia patients constrain chromatin accessibility. The interaction between PU.1 and IRF4 at EICE composite elements is a well-characterized functional partnership essential for B cell gene regulation. Reason: The interaction between IRF4 and PU.1/SPI1 is functionally critical and well-characterized, but "protein binding" is too vague. IRF4-PU.1 interaction at EICE elements is a core mechanism for IRF4 target gene selection in B cells. A more specific term describing transcription factor binding or DNA-binding transcription factor binding would be more informative. Proposed replacements: DNA-binding transcription factor binding Supporting Evidence: PMID:33951726 Consistent with intact PEST domains, all three proteins coimmunoprecipitated with IRF4 and IRF8 (Fig. S5 E).
GO:1990837 sequence-specific double-stranded DNA binding	IDA PMID:28473536 Impact of cytosine methylation on DNA binding specificities ...	ACCEPT	Summary: IDA annotation from Yin et al. (2017) Science, a systematic analysis of DNA binding specificities of 542 human TFs using SELEX. IRF4 DNA binding specificity was characterized in this high-throughput but rigorous assay. Reason: This annotation is well-supported. The SELEX-based analysis provided direct experimental evidence for sequence-specific double-stranded DNA binding by IRF4. The study identified binding motifs for hundreds of TFs using purified proteins, providing direct biochemical evidence of IRF4's DNA binding activity. Supporting Evidence: PMID:28473536 By analysis of 542 human TFs with methylation-sensitive SELEX (systematic evolution of ligands by exponential enrichment), we found that there are also many TFs that prefer CpG-methylated sequences.
GO:0000785 chromatin	ISA GO_REF:0000113	ACCEPT	Summary: ISA annotation from TFClass database (tfclass:3.5.3), placing IRF4 at chromatin. As a DNA-binding transcription factor, IRF4 associates with chromatin at its target gene regulatory regions. Reason: Correct annotation. IRF4 binds chromatin at cis-regulatory elements of target genes. The TFClass-based annotation appropriately recognizes that sequence-specific DNA-binding TFs are located at chromatin.
GO:0000981 DNA-binding transcription factor activity, RNA polymerase II-specific	ISA GO_REF:0000113	ACCEPT	Summary: ISA annotation from TFClass database classifying IRF4 as a sequence-specific DNA-binding transcription factor (class 3.5.3 - Tryptophan cluster factors: IRF subfamily). Reason: Correct annotation consistent with IRF4's classification as an IRF family transcription factor. This duplicates the IBA annotation but provides independent evidence from the TFClass classification system.
GO:0120162 positive regulation of cold-induced thermogenesis	ISS PMID:24995979 IRF4 is a key thermogenic transcriptional partner of PGC-1α.	KEEP AS NON CORE	Summary: ISS annotation based on mouse IRF4 ortholog (Q64287) data from PMID:24995979, transferred by YuBioLab. Mouse IRF4 promotes thermogenic gene expression in brown adipose tissue. Reason: This is the same annotation as the IEA Ensembl Compara transfer. While the mouse data supports a role for IRF4 in thermogenesis, this is clearly a non-core function for a protein primarily characterized as an immune system transcription factor. The human relevance is uncertain. Supporting Evidence: PMID:24995979 IRF4 is induced by cold and cAMP in adipocytes and is sufficient to promote increased thermogenic gene expression, energy expenditure, and cold tolerance.
GO:0000978 RNA polymerase II cis-regulatory region sequence-specific DNA binding	IDA PMID:12374808 Modulation of T cell cytokine production by interferon regul...	ACCEPT	Summary: IDA annotation from Hu et al. (2002) showing IRF4 binds to a specific site in the IL-4 promoter adjacent to an NFAT binding element, as demonstrated by EMSA and reporter assays in Jurkat T cells. Reason: Direct experimental evidence from EMSA showing IRF4 binds a specific DNA site in the IL-4 promoter. This is a core molecular function supported by detailed promoter analysis. Supporting Evidence: PMID:12374808 A detailed analysis of the effects of IRF-4 on the IL-4 promoter reveals that IRF-4 binds to a site adjacent to a functionally important NFAT binding element and that IRF-4 cooperates with NFATc1.
GO:0001228 DNA-binding transcription activator activity, RNA polymerase II-specific	IDA PMID:12374808 Modulation of T cell cytokine production by interferon regul...	ACCEPT	Summary: IDA annotation from Hu et al. (2002) showing IRF4 transactivates luciferase reporter constructs driven by IL-2 and IL-4 promoters in Jurkat T cells. Stable IRF4 expression enhanced IL-2 synthesis and enabled production of IL-4, IL-10, and IL-13. Reason: Direct evidence that IRF4 functions as a transcriptional activator. This is the most specific appropriate MF term per GO-CAM TF annotation guidelines. The reporter assays directly demonstrate transcription activator activity. Supporting Evidence: PMID:12374808 Transient transfection assays indicate that IRF-4 can transactivate luciferase reporter constructs driven by either the human IL-2 or the human IL-4 promoter.
GO:0045944 positive regulation of transcription by RNA polymerase II	IDA PMID:12374808 Modulation of T cell cytokine production by interferon regul...	ACCEPT	Summary: IDA annotation from Hu et al. (2002) demonstrating that IRF4 positively regulates Pol II transcription of cytokine genes in T cells, as shown by reporter assays and endogenous cytokine production measurements. Reason: Direct experimental evidence showing IRF4 activates transcription from IL-2 and IL-4 promoters. This biological process annotation is the appropriate complement to the MF annotation for transcription activator activity. Supporting Evidence: PMID:12374808 We demonstrate that stable expression of IRF-4 in Jurkat T cells not only leads to a strong enhancement in the synthesis of interleukin (IL)-2, but also enables these cells to start producing considerable amounts of IL-4, IL-10, and IL-13.
GO:0016020 membrane	HDA PMID:19946888 Defining the membrane proteome of NK cells.	MARK AS OVER ANNOTATED	Summary: HDA annotation from Ghosh et al. (2010), a proteomics study defining the membrane proteome of NK cells (YTS cell line). IRF4 was identified among 1843 proteins in membrane fractions. Reason: IRF4 is a nuclear transcription factor and not a membrane protein. Its detection in membrane fractions in this proteomics study likely represents contamination from nuclear/cytoplasmic fractions or transient association during cell lysis. The study itself notes that approximately 60% of identified proteins were not predicted membrane proteins. This annotation does not reflect a genuine biological function or localization of IRF4. Supporting Evidence: PMID:19946888 The remaining species were largely involved in cellular processes and molecular functions that could be predicted to be transiently associated with membranes.
GO:0005829 cytosol	TAS Reactome:R-HSA-1015702	ACCEPT	Summary: TAS annotation from Reactome pathway R-HSA-1015702 (Expression of IFN-induced genes), placing IRF4 in the cytosol. This represents a Reactome model where IRF4 is produced in the cytosol before translocation to the nucleus. Reason: IRF4 is synthesized in the cytosol and can be found there. While its primary functional location is the nucleus, cytosolic localization is supported by UniProt and the Reactome pathway models. The cytosol annotation from Reactome likely represents the newly synthesized protein pool.
GO:0005829 cytosol	TAS Reactome:R-HSA-1031716	ACCEPT	Summary: TAS annotation from Reactome pathway R-HSA-1031716 (Expression of IFNG-stimulated genes). Reason: Duplicate cytosol annotation from a different Reactome pathway. Acceptable as IRF4 is present in the cytosol.
GO:0005829 cytosol	TAS Reactome:R-HSA-6790041	ACCEPT	Summary: TAS annotation from Reactome pathway R-HSA-6790041 (Expression of STAT3-upregulated cytosolic proteins). Reason: Duplicate cytosol annotation from a Reactome pathway modeling STAT3-dependent IRF4 expression. Acceptable as IRF4 is present in the cytosol.
GO:0005829 cytosol	TAS Reactome:R-HSA-9851117	ACCEPT	Summary: TAS annotation from Reactome pathway R-HSA-9851117 (NPM1-ALK- and p-STAT3-dependent IRF4 gene expression). Reason: Duplicate cytosol annotation from a Reactome pathway modeling ALK-STAT3-dependent IRF4 expression in lymphoma contexts.
GO:0003700 DNA-binding transcription factor activity	ISS GO_REF:0000024	ACCEPT	Summary: Manual transfer from mouse IRF4 (Q64287) for DNA-binding transcription factor activity. Reason: Correct annotation. IRF4 is a DNA-binding transcription factor in both mouse and human. This broader term is a parent of the more specific GO:0000981 and GO:0001228 that are also annotated with stronger evidence.
GO:0042832 defense response to protozoan	ISS GO_REF:0000024	KEEP AS NON CORE	Summary: Manual transfer from mouse IRF4 for defense response to protozoan. Mouse Irf4-/- mice show impaired immune responses to Leishmania and Toxoplasma. Reason: Same annotation as the IEA Ensembl Compara transfer. IRF4 is required for effective immune responses against protozoan parasites through its role in T cell differentiation, but this is a downstream consequence rather than a core function.
GO:0043565 sequence-specific DNA binding	ISS GO_REF:0000024	ACCEPT	Summary: Manual transfer from mouse IRF4 for sequence-specific DNA binding. Reason: Correct and consistent with experimental evidence. IRF4 binds DNA in a sequence-specific manner through its tryptophan pentad repeat domain.
GO:0072540 T-helper 17 cell lineage commitment	ISS GO_REF:0000024	KEEP AS NON CORE	Summary: Manual transfer from mouse IRF4 for Th17 cell lineage commitment. Mouse Irf4-/- mice fail to develop Th17 cells. Reason: Same annotation as the IEA transfer. IRF4 is essential for Th17 differentiation, but this is one of several immune cell differentiation programs regulated by IRF4 and is a non-core annotation.
GO:0005634 nucleus	IC PMID:12374808 Modulation of T cell cytokine production by interferon regul...	ACCEPT	Summary: Curator inference that IRF4 is nuclear, based on evidence that it functions as a DNA-binding transcription factor (GO:0003700). Inferred from PMID:12374808 showing IRF4 transactivates promoter-reporter constructs and binds DNA. Reason: Logical inference that a DNA-binding transcription factor localizes to the nucleus. This is confirmed by direct evidence (IDA from HPA, IMP from PMID:36917008). Supporting Evidence: PMID:12374808 Transient transfection assays indicate that IRF-4 can transactivate luciferase reporter constructs driven by either the human IL-2 or the human IL-4 promoter.
GO:0032733 positive regulation of interleukin-10 production	IDA PMID:12374808 Modulation of T cell cytokine production by interferon regul...	KEEP AS NON CORE	Summary: Hu et al. (2002) showed that stable expression of IRF4 in Jurkat T cells enabled production of IL-10. IRF4 deficiency in mouse T cells profoundly impairs cytokine production. Reason: This is a legitimate downstream effect of IRF4 transcriptional activity in T cells. However, positive regulation of IL-10 production is a downstream consequence of IRF4's transcription factor activity rather than a core function. IRF4 likely activates IL-10 transcription indirectly through its effects on T cell differentiation programs. Supporting Evidence: PMID:12374808 We demonstrate that stable expression of IRF-4 in Jurkat T cells not only leads to a strong enhancement in the synthesis of interleukin (IL)-2, but also enables these cells to start producing considerable amounts of IL-4, IL-10, and IL-13.
GO:0032736 positive regulation of interleukin-13 production	IDA PMID:12374808 Modulation of T cell cytokine production by interferon regul...	KEEP AS NON CORE	Summary: Hu et al. (2002) showed that stable expression of IRF4 in Jurkat T cells enabled production of IL-13. Reason: Legitimate downstream effect of IRF4 transcriptional activity. IL-13 production is enabled by IRF4 in the context of Th2 differentiation. This represents a specific downstream output of IRF4's transcription factor activity rather than a core molecular function. Supporting Evidence: PMID:12374808 We demonstrate that stable expression of IRF-4 in Jurkat T cells not only leads to a strong enhancement in the synthesis of interleukin (IL)-2, but also enables these cells to start producing considerable amounts of IL-4, IL-10, and IL-13.
GO:0032743 positive regulation of interleukin-2 production	IDA PMID:12374808 Modulation of T cell cytokine production by interferon regul...	KEEP AS NON CORE	Summary: Hu et al. (2002) showed that stable IRF4 expression in Jurkat T cells strongly enhanced IL-2 synthesis. IRF4 transactivates luciferase reporters driven by the human IL-2 promoter. Reason: Legitimate downstream effect of IRF4 transcriptional activity. IL-2 is a direct transcriptional target of IRF4, as shown by promoter-reporter assays. While this is a more direct relationship than some other cytokine regulation annotations, it represents a specific downstream output of IRF4's core transcription factor activity rather than the core function itself. Supporting Evidence: PMID:12374808 We demonstrate that stable expression of IRF-4 in Jurkat T cells not only leads to a strong enhancement in the synthesis of interleukin (IL)-2, but also enables these cells to start producing considerable amounts of IL-4, IL-10, and IL-13.
GO:0032753 positive regulation of interleukin-4 production	IDA PMID:12374808 Modulation of T cell cytokine production by interferon regul...	KEEP AS NON CORE	Summary: Hu et al. (2002) showed that stable IRF4 expression in Jurkat T cells enabled production of IL-4. IRF4 transactivates the IL-4 promoter and binds a site adjacent to an NFAT element, cooperating with NFATc1. Reason: Legitimate and well-supported downstream effect. IRF4 directly binds and activates the IL-4 promoter. This is a specific and well-characterized output of IRF4's transcription factor activity in the context of Th2 differentiation. Kept as non-core because it represents one specific target gene regulation downstream of the core TF activity. Supporting Evidence: PMID:12374808 A detailed analysis of the effects of IRF-4 on the IL-4 promoter reveals that IRF-4 binds to a site adjacent to a functionally important NFAT binding element and that IRF-4 cooperates with NFATc1.
GO:0042110 T cell activation	NAS PMID:12374808 Modulation of T cell cytokine production by interferon regul...	KEEP AS NON CORE	Summary: NAS annotation from Hu et al. (2002) for T cell activation. The paper discusses IRF4's role in modulating T cell cytokine production, noting that IRF4 deficiency impairs mature CD4+ T cell function. Reason: IRF4 is important for T cell activation and function, but this is a downstream organismal process rather than a direct molecular activity. The NAS evidence code indicates this is based on statements in the paper rather than direct experimental demonstration in this study. T cell activation is a broad term encompassing many steps, and IRF4 contributes primarily through its transcriptional programs that enable cytokine production. Supporting Evidence: PMID:12374808 Interferon regulatory factor (IRF)-4 is a lymphoid-restricted member of the interferon regulatory factor family of transcriptional regulators, whose deficiency leads to a profound impairment in the ability of mature CD4(+) T cells to produce cytokines.
GO:0045622 regulation of T-helper cell differentiation	NAS PMID:12374808 Modulation of T cell cytokine production by interferon regul...	ACCEPT	Summary: NAS annotation for regulation of T-helper cell differentiation based on Hu et al. (2002). The paper discusses how IRF4 controls T cell cytokine production, which is closely linked to Th cell differentiation programs. Reason: IRF4 is genuinely critical for T-helper cell differentiation, including Th2, Th9, and Th17 lineages. While the evidence code is NAS (non-traceable author statement), this function is extremely well-established in subsequent literature. IRF4 is a master regulator of multiple Th cell differentiation programs. Supporting Evidence: PMID:12374808 These studies thus support the notion that IRF-4 represents one of the lymphoid-specific components that control the ability of T lymphocytes to produce a distinctive array of cytokines.
GO:0045893 positive regulation of DNA-templated transcription	IDA PMID:12374808 Modulation of T cell cytokine production by interferon regul...	ACCEPT	Summary: IDA annotation from Hu et al. (2002) showing IRF4 positively regulates DNA-templated transcription. Demonstrated by transactivation of IL-2 and IL-4 promoter-reporter constructs and enhancement of endogenous cytokine gene expression. Reason: Direct experimental evidence supporting IRF4 as a positive regulator of transcription. This is a core biological process annotation complementing the MF transcription activator annotations. Supporting Evidence: PMID:12374808 Transient transfection assays indicate that IRF-4 can transactivate luciferase reporter constructs driven by either the human IL-2 or the human IL-4 promoter.
GO:1900100 positive regulation of plasma cell differentiation	NAS PMID:29537367 IRF4 haploinsufficiency in a family with Whipple's disease.	NEW	Summary: IRF4 is essential for plasma cell differentiation. Loss-of-function variants in IRF4 cause combined immunodeficiency (IMD131) characterized by low immunoglobulin levels and low plasma cell counts (PMID:29537367, PMID:36662884, PMID:36917008). IRF4 cooperates with BLIMP1/XBP1 to drive the plasma cell differentiation program. In multiple myeloma, IRF4 is a lineage addiction factor for malignant plasma cells. Reason: This is a major gap in the current annotation set. Plasma cell differentiation is one of the best-established and most important biological functions of IRF4, yet it is not annotated. Human genetic evidence from IMD131 patients directly demonstrates IRF4's requirement for plasma cell differentiation. The Reactome and UniProt entries both reference IRF4's role in B cell/plasma cell biology. Supporting Evidence: PMID:29537367 AD IRF4 deficiency can underlie WD by haploinsufficiency, with age-dependent incomplete penetrance. PMID:36917008 Expression of the mutant IRF4 protein in control lymphoblastoid B cell lines reduced the expression of BLIMP-1 and XBP1 (key transcription factors in plasma cell differentiation).

Core Functions

IRF4 functions as a sequence-specific DNA-binding transcriptional activator. It binds ISRE (interferon-stimulated response element) motifs and composite elements (EICE with PU.1/SPI-B, AICE with BATF/JUN) to activate transcription of target genes. The N-terminal tryptophan pentad repeat domain (aa 21-129) mediates DNA binding, while the C-terminal IRF-associated domain (IAD) mediates heterodimerization with partner TFs. IRF4 has intrinsically weak solo DNA-binding activity and acquires target gene specificity through its partner TFs.

Molecular Function:

DNA-binding transcription activator activity, RNA polymerase II-specific

Directly Involved In:

regulation of transcription by RNA polymerase II positive regulation of transcription by RNA polymerase II regulation of T-helper cell differentiation

Cellular Locations:

nucleus chromatin

Supporting Evidence:

PMID:12374808
Transient transfection assays indicate that IRF-4 can transactivate luciferase reporter constructs driven by either the human IL-2 or the human IL-4 promoter.

IRF4 regulates Pol II-dependent transcription of target genes involved in immune cell differentiation and function, including cytokine genes (IL-2, IL-4, IL-10, IL-13, IL-17), immunoglobulin genes, and differentiation program genes. It primarily functions as a transcriptional activator, though context-dependent repressive roles have been described. IRF4 cooperates with PU.1/SPI-B at EICE elements in B cells and with BATF/JUN at AICE elements in T cells.

Molecular Function:

DNA-binding transcription factor activity, RNA polymerase II-specific

Directly Involved In:

positive regulation of DNA-templated transcription immune system process

Cellular Locations:

nucleus nucleoplasm

References

GO_REF:0000002

Gene Ontology annotation through association of InterPro records with GO terms

GO_REF:0000024

Manual transfer of experimentally-verified manual GO annotation data to orthologs by curator judgment of sequence similarity

GO_REF:0000033

Annotation inferences using phylogenetic trees

GO_REF:0000043

Gene Ontology annotation based on UniProtKB/Swiss-Prot keyword mapping

GO_REF:0000044

Gene Ontology annotation based on UniProtKB/Swiss-Prot Subcellular Location vocabulary mapping, accompanied by conservative changes to GO terms applied by UniProt

GO_REF:0000052

Gene Ontology annotation based on curation of immunofluorescence data

GO_REF:0000107

Automatic transfer of experimentally verified manual GO annotation data to orthologs using Ensembl Compara

GO_REF:0000113

Gene Ontology annotation of human sequence-specific DNA binding transcription factors (DbTFs) based on the TFClass database

GO_REF:0000117

Electronic Gene Ontology annotations created by ARBA machine learning models

GO_REF:0000120

Combined Automated Annotation using Multiple IEA Methods

PMID:12374808

Modulation of T cell cytokine production by interferon regulatory factor-4.

IRF4 is lymphoid-restricted and its deficiency impairs CD4+ T cell cytokine production

"Interferon regulatory factor (IRF)-4 is a lymphoid-restricted member of the interferon regulatory factor family of transcriptional regulators, whose deficiency leads to a profound impairment in the ability of mature CD4(+) T cells to produce cytokines."
Stable IRF4 expression in Jurkat T cells enhances IL-2 and enables IL-4, IL-10, IL-13 production

"We demonstrate that stable expression of IRF-4 in Jurkat T cells not only leads to a strong enhancement in the synthesis of interleukin (IL)-2, but also enables these cells to start producing considerable amounts of IL-4, IL-10, and IL-13."
IRF4 transactivates IL-2 and IL-4 promoter-reporter constructs

"Transient transfection assays indicate that IRF-4 can transactivate luciferase reporter constructs driven by either the human IL-2 or the human IL-4 promoter."
IRF4 binds a site in the IL-4 promoter adjacent to an NFAT binding element and cooperates with NFATc1

"A detailed analysis of the effects of IRF-4 on the IL-4 promoter reveals that IRF-4 binds to a site adjacent to a functionally important NFAT binding element and that IRF-4 cooperates with NFATc1."

PMID:19946888

Defining the membrane proteome of NK cells.

Proteomics study of NK cell membrane fractions identified 1843 proteins including IRF4

"The remaining species were largely involved in cellular processes and molecular functions that could be predicted to be transiently associated with membranes."
Approximately 60% of identified proteins were not predicted membrane proteins

"approximately 40% of the identified proteins were predicted as plausible membrane proteins."

PMID:21903422

Mapping a dynamic innate immunity protein interaction network regulating type I interferon production.

Large-scale interactome mapping (HI5) of innate immune signaling

"IKBKAP interacts with IRF4 and negatively regulates HSV-induced IFN production."
IKBKAP (ELP1) interacts with IRF4 and negatively regulates HSV-induced IFN production

"IKBKAP interacts with IRF4 and negatively regulates HSV-induced IFN production."
IRF4 interactions with IRAK1, TLK2, YTHDC2 detected

"Fifty-eight baits were associated with 260 interacting proteins forming a human innate immunity interactome for type I interferon (HI5) of 401 unique interactions"

PMID:24995979

IRF4 is a key thermogenic transcriptional partner of PGC-1α.

Mouse Irf4 promotes thermogenic gene expression in brown adipose tissue

"Here, we identify interferon regulatory factor 4 (IRF4) as a dominant transcriptional effector of thermogenesis. IRF4 is induced by cold and cAMP in adipocytes and is sufficient to promote increased thermogenic gene expression, energy expenditure, and cold tolerance."

PMID:28473536

Impact of cytosine methylation on DNA binding specificities of human transcription factors.

Systematic SELEX analysis of 542 human TFs including IRF4

"By analysis of 542 human TFs with methylation-sensitive SELEX (systematic evolution of ligands by exponential enrichment), we found that there are also many TFs that prefer CpG-methylated sequences."
Provided direct biochemical evidence of IRF4 sequence-specific DNA binding

"In this work, we performed systematic analysis of DNA binding specificities of full-length TFs and eDBDs using unmethylated and CpG-methylated DNA ligands."

PMID:29537367

IRF4 haploinsufficiency in a family with Whipple's disease.

R98W variant causes loss of DNA-binding transcription activator activity

"We found that R98W was loss-of-function, modified the transcriptome of heterozygous leukocytes following Tw stimulation, and was not dominant-negative."
RC98-99AA double mutant also loses activity

"IRF4 R98A-C99A, which is LOF for DNA binding (Brass et al., 1999), was included as a negative control."
IRF4 haploinsufficiency causes combined immunodeficiency (IMD131)

"AD IRF4 deficiency can underlie WD by haploinsufficiency, with age-dependent incomplete penetrance."

PMID:32296183

A reference map of the human binary protein interactome.

HuRI systematic yeast two-hybrid interactome mapping

"Here we present a human 'all-by-all' reference interactome map of human binary protein interactions, or 'HuRI'."
IRF4 interactions with GIPC2 and TSEN54 detected

"Here we present a human 'all-by-all' reference interactome map of human binary protein interactions, or 'HuRI'. With approximately 53,000 protein-protein interactions, HuRI has approximately four times as many such interactions as there are high-quality curated interactions from small-scale studies."

PMID:33951726

Constrained chromatin accessibility in PU.1-mutated agammaglobulinemia patients.

IRF4 directly interacts with PU.1 (SPI1)

"Consistent with intact PEST domains, all three proteins coimmunoprecipitated with IRF4 and IRF8 (Fig. S5 E)."
PU.1 mutations impair chromatin accessibility in B cell development

"Once in open chromatin, PU.1 can directly control gene expression by binding genetic regulatory elements and can also more broadly influence transcription by recruiting nonpioneers, such as interferon regulatory factors (IRFs), to otherwise inaccessible genomic regions (Ciau-Uitz et al., 2013; Heinz et al., 2013; Pongubala and Atchison, 1997; Sherwood et al., 2014)."

PMID:36662884

A multimorphic mutation in IRF4 causes human autosomal dominant combined immunodeficiency.

T95R variant gains neomorphic DNA binding to GATA sequences

"IRF4T95R behaved as a gain-of-function hypermorph by binding to DNA with higher affinity than IRF4WT. Despite this increased affinity for DNA, the transcriptional activity on IRF4 canonical genes was reduced, showcasing a hypomorphic activity of IRF4T95R."
Decreased activation from canonical ISRE reporter

"Simultaneously, IRF4T95R functions as a neomorph by binding to noncanonical DNA sites to alter the gene expression profile, including the transcription of genes exclusively induced by IRF4T95R but not by IRF4WT."
Confirms wildtype IRF4 DNA-binding transcription activator activity

"Interferon regulatory factor 4 (IRF4) is a transcription factor (TF) and key regulator of immune cell development and function."

PMID:36917008

A neomorphic mutation in the interferon activation domain of IRF4 causes a dominant primary immunodeficiency.

F359L variant loses DNA-binding transcription activator activity

"The mutant IRF4 failed to efficiently regulate the transcriptional activity of interferon-stimulated response elements (ISREs)."
No effect on subcellular location (nucleus/cytoplasm)

"The IRF4 F359L and IRF4 WT proteins were similar with regard to their subcellular localization in the cytoplasm and the nucleus"
Confirms wildtype IRF4 functions as transcriptional activator in nucleus

"Expression of the mutant IRF4 protein in control lymphoblastoid B cell lines reduced the expression of BLIMP-1 and XBP1 (key transcription factors in plasma cell differentiation)."

Reactome:R-HSA-1015702

Expression of IFN-induced genes

Reactome:R-HSA-1031716

Expression of IFNG-stimulated genes

Reactome:R-HSA-6790041

Expression of STAT3-upregulated cytosolic proteins

Reactome:R-HSA-9851117

NPM1-ALK- and p-STAT3-dependent IRF4 gene expression

Reactome:R-HSA-9907145

IRF4 binds the TYR promoter

Reactome:R-HSA-9907147

MITF-M-dependent IRF4 gene expression

Deep Research

Falcon

(IRF4-deep-research-falcon.md)

this with annotations you find in gene/protein databases, but these can be outdated or inaccurate. Falcon Edison Scientific Literature 40 citations 2026-02-14T14:27:35.568042

The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.

You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.

We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.

We are interested in where in or outside the cell the gene product carries out its function.

We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.

Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.

Comprehensive Research Report: Human IRF4 (UniProt Q15306)

Identity, Domains, and Definitions
- Identity verification: IRF4 (also known as MUM1/LSIRF) is a human interferon regulatory factor family transcription factor, largely restricted to the immune system. It is induced primarily by antigen receptor signaling (TCR/BCR), IL-4, CD40, and LPS, rather than by type I/II interferons, consistent with UniProt Q15306 annotations and IRF family membership (DBD plus IAD) (lu2023regulatoryeffectsof pages 1-2, gabele2025elucidatingtherole pages 15-17, gabele2025elucidatingtherolea pages 15-17).
- Domain architecture: IRF4 contains an N‑terminal tryptophan‑rich DNA‑binding domain (DBD) that recognizes ISRE-like GAAA motifs, and a C‑terminal IRF‑associated domain (IAD) mediating homo/hetero‑dimerization. Literature also describes an autoinhibitory region and a nuclear localization signal. Structural/biophysical studies of the human IRF4 DBD and mutants support this architecture and its functional consequences (e.g., altered DNA-binding kinetics and nuclear partitioning) (tatum2025structuralbiophysicaland pages 1-2, tatum2025structuralbiophysicaland pages 20-23, gabele2025elucidatingtherole pages 15-17, gabele2025elucidatingtherolea pages 15-17). URLs/dates: Frontiers Immunology, Feb 2023, https://doi.org/10.3389/fimmu.2023.1086803; bioRxiv, Mar 2025, https://doi.org/10.1101/2025.03.12.642038.

Cellular Localization
- IRF4 functions as a nuclear transcription factor. DBD mutant analyses show changes in nuclear partitioning (e.g., K123R nearly entirely nuclear), reinforcing nuclear localization as essential to activity (bioRxiv preprint; interpret with caution pending peer review) (tatum2025structuralbiophysicaland pages 20-23). URL/date: bioRxiv, Mar 2025, https://doi.org/10.1101/2025.03.12.642038.

Primary Molecular Function and DNA-Binding Mechanisms
- IRF4 is a context‑dependent transcription factor with intrinsically weak solo DNA binding. It acquires specificity and affinity via composite elements and partner TFs: with PU.1/Spi-B at EICEs in B cells, and with AP‑1 family (e.g., BATF/Jun) at AICEs in T cells; partner sets include AHR, FOXP3, IRF8 in Treg/Th17 contexts. ChIP-seq/proteomic interactome mapping in T cells shows enhancer‑biased binding and extensive partner-dependence for target selection (bioRxiv, Sep 2023) (gabele2023unveilingirf4steeredregulation pages 17-19, gabele2023unveilingirf4steeredregulation pages 12-14, gabele2025elucidatingtherole pages 15-17, gabele2025elucidatingtherolea pages 15-17). URL/date: bioRxiv, Sep 2023, https://doi.org/10.1101/2023.09.14.557376.
- Induction and upstream control: TCR signaling (notably via NF‑κB/c‑Rel) drives IRF4 expression in a dose‑dependent fashion; IRF4 is further integrated with mTOR, ITK, NFAT, and STAT3 signaling, and cross‑regulated by lineage TFs (T‑bet, GATA3, RORγt, FOXP3) (gabele2025elucidatingtherole pages 15-17, gabele2025elucidatingtherolea pages 15-17). URL/date: 2025 thesis/overview (unknown journal; mechanistic details concordant with 2023–2024 primary studies listed elsewhere).

Roles in Lymphocyte Biology and Innate Compartments
- CD4+ T cells: IRF4 is essential for Th17 differentiation (binding/promoting Il17a/f, Il21, Rorc) and modulates Treg effector programs; it can either sustain effector functions (e.g., Th1/CTL) or participate in exhaustion programs depending on partner context in the TME (lu2023regulatoryeffectsof pages 1-2, gabele2025elucidatingtherole pages 15-17, gabele2025elucidatingtherolea pages 15-17, gabele2023unveilingirf4steeredregulation pages 17-19). URLs/dates: Frontiers Immunology, Feb 2023, https://doi.org/10.3389/fimmu.2023.1086803; bioRxiv, Sep 2023, https://doi.org/10.1101/2023.09.14.557376.
- B cells/plasma cell biology: IRF4 is a lineage determinant for plasmacytic differentiation and plasma‑cell identity (with BLIMP1/XBP1), and is highly expressed in plasma cells; dysregulation underlies malignant plasma‑cell survival in MM (“IRF4 addiction”). Recent therapeutic studies in MM (below) recapitulate this dependency and its enhancer basis (davis2024mycinhibitionpotentiates pages 15-16, welsh2024transcriptionalheterogeneityovercomes pages 1-3). URLs/dates: Clin Cancer Res, May/Jul 2024, https://doi.org/10.1158/1078-0432.ccr-24-0256; Blood Cancer Discovery, Sep 2024, https://doi.org/10.1158/2643-3230.bcd-23-0062.
- Myeloid and other immune cells: IRF4 regulates programs in macrophages, dendritic cells, and contributes to shaping immunosuppressive cells (e.g., Tregs, MDSCs) in the tumor microenvironment (lu2023regulatoryeffectsof pages 1-2). URL/date: Frontiers Immunology, Feb 2023, https://doi.org/10.3389/fimmu.2023.1086803.

Key Pathways and Crosstalk
- BCR/TCR and NF‑κB: Antigen‑receptor engagement induces IRF4 via NF‑κB (c‑Rel), integrating with AP‑1 and IRF partners at composite elements (gabele2025elucidatingtherole pages 15-17, gabele2025elucidatingtherolea pages 15-17, gabele2023unveilingirf4steeredregulation pages 17-19).
- JAK–STAT: STAT3 cooperates with IRF4 in Th17 programming; IRF4–STAT3 interactions have been detected in Th17 contexts (gabele2023unveilingirf4steeredregulation pages 17-19, gabele2025elucidatingtherole pages 15-17).
- mTOR: mTOR activity modulates IRF4 levels and function during lymphocyte activation and differentiation (gabele2025elucidatingtherole pages 15-17, gabele2025elucidatingtherolea pages 15-17).

Disease Relevance and Genetics
- Multiple myeloma (MM): IRF4 is a lineage oncogene/dependency; the canonical therapeutic axis is CRBN→IKZF1/3 degradation→downregulation of IRF4 and MYC. Failure to suppress IRF4/MYC underlies IMiD resistance; compensatory AP‑1 (BATF) and ETS (ETV4) mechanisms can maintain enhancer activity at IRF4/MYC super‑enhancers, preserving survival programs (davis2024mycinhibitionpotentiates pages 15-16, welsh2024transcriptionalheterogeneityovercomes pages 19-20, welsh2024transcriptionalheterogeneityovercomes pages 1-3, teoh2024resistancetoimmunomodulatory pages 6-7, teoh2024resistancetoimmunomodulatory pages 12-14). URLs/dates: Clin Cancer Res, May/Jul 2024, https://doi.org/10.1158/1078-0432.ccr-24-0256; Blood Cancer Discovery, Sep 2024, https://doi.org/10.1158/2643-3230.bcd-23-0062; Haematologica, Nov 2024, https://doi.org/10.3324/haematol.2024.285636.
- DLBCL/LBCL with IRF4 rearrangement: IRF4‑rearranged LBCL (often pediatric/young adult) shows recurrent IRF4 mutations, frequent NF‑κB pathway co‑alterations (CARD11, CD79B, MYD88), and distinct copy‑number patterns, with prognostic implications (ramiszaldivar2020distinctmolecularprofile pages 1-2). URL/date: Blood, Jan 2020, https://doi.org/10.1182/blood.2019002699.
- Autoimmunity/inflammation and TME: IRF4 coordinates immunity and tolerance, with context‑dependent roles in Th subsets, Treg function, macrophage polarization, and T‑cell exhaustion in tumors (lu2023regulatoryeffectsof pages 1-2, gabele2023unveilingirf4steeredregulation pages 17-19).

Recent Developments (2023–2024) and Applications
- Enhancer‑centric therapies and resistance in MM:
- Super‑enhancer disrupting combinations: IKZF1/3 degraders (IMiDs/CELMoDs) reduce IRF4/MYC; EP300/CBP catalytic inhibition further suppresses IRF4/MYC and synergizes with IMiDs in vitro/in vivo; however, AP‑1/BATF‑driven maintenance of IRF4/MYC can mediate escape (welsh2024transcriptionalheterogeneityovercomes pages 1-3). URL/date: Blood Cancer Discovery, Sep 2024, https://doi.org/10.1158/2643-3230.bcd-23-0062.
- Quantitative profiling: 48 myeloma cell lines profiled with pomalidomide (200 nM, 3 days) delineated IMiD sensitivity vs resistance; EP300+IMiD combinations produced deeper MYC/IRF4 suppression but remained vulnerable to BATF‑mediated programs (welsh2024transcriptionalheterogeneityovercomes pages 1-3).
- Systematic resistance biology and statistics: A 2024 review collated that many Pom‑treated resistant lines remained viable despite marked IKZF1/3 loss; compensatory TFs BATF (upregulated at relapse in a cohort of N=35) and ETV4 (with poorer survival in MMRF CoMMpass N=484) maintained BRD4/P300 occupancy and enhancer function, sustaining IRF4/MYC (teoh2024resistancetoimmunomodulatory pages 6-7). URL/date: Haematologica, Nov 2024, https://doi.org/10.3324/haematol.2024.285636.
- Downstream targeting of MYC: The MYC inhibitor MYCi975 exerted potent anti‑MM effects in IMiD‑naïve and refractory primary samples, enhanced memory CD8+ T‑cell cytotoxicity, and synergized with pomalidomide to re‑sensitize refractory samples, functionally countering persistent IRF4–MYC programs (davis2024mycinhibitionpotentiates pages 15-16). URL/date: Clin Cancer Res, May/Jul 2024, https://doi.org/10.1158/1078-0432.ccr-24-0256.
- SUMOylation inhibition: The SUMO E1 inhibitor TAK‑981 reduced IRF4 and c‑MYC through both transcriptional and post‑translational mechanisms and enhanced lenalidomide sensitivity in resistant cell lines and primary MM samples, offering a CRBN‑independent route to downregulate IRF4 (davis2024mycinhibitionpotentiates pages 1-3). URL/date: Cancer Gene Therapy, Mar 2023, https://doi.org/10.1038/s41417-022-00450-9.

Mechanistic Synthesis: IRF4 in Pathways and Partner Networks
- Composite motif logic and partner choice (PU.1/EICE in B cells; BATF/AP‑1/AICE in T cells; AHR/FOXP3/IRF8 in lineage‑specific contexts) underlies IRF4’s target gene selection and explains its divergent roles in effector vs regulatory programs. Enhancer‑biased occupancy and reliance on coactivators (e.g., BRD4, EP300/CBP) connect IRF4 to druggable chromatin machinery (gabele2023unveilingirf4steeredregulation pages 17-19, gabele2023unveilingirf4steeredregulation pages 12-14, welsh2024transcriptionalheterogeneityovercomes pages 1-3, welsh2024transcriptionalheterogeneityovercomes pages 19-20).

Expert Analysis and Opinions from Authoritative Sources
- The 2024 Blood Cancer Discovery study and commentary emphasize that sustained IRF4/MYC expression via transcriptional plasticity (AP‑1/BATF, ETS/ETV4, coactivator compensation) drives IMiD resistance, and that combining IMiDs with p300/CBP inhibition deepens IRF4/MYC suppression but requires strategies to prevent AP‑1‑driven escape (welsh2024transcriptionalheterogeneityovercomes pages 1-3, welsh2024transcriptionalheterogeneityovercomes pages 19-20). URL/date: Blood Cancer Discovery, Sep 2024, https://doi.org/10.1158/2643-3230.bcd-23-0062.
- The 2024 Haematologica review systematically outlines CRBN‑dependent and CRBN‑independent resistance pathways, highlighting that the rate (kinetics) of IKZF1/3 degradation determines IRF4 modulation and clinical response, and pointing to compensatory TFs and metabolic rewiring as targets to collapse IRF4/MYC maintenance (teoh2024resistancetoimmunomodulatory pages 12-14, teoh2024resistancetoimmunomodulatory pages 6-7). URL/date: Haematologica, Nov 2024, https://doi.org/10.3324/haematol.2024.285636.

Relevant Statistics and Data (2023–2024)
- Pomalidomide resistance profiles: An integrative 2024 review reported that a large majority of pomalidomide‑treated resistant MM cell lines remained viable despite substantial IKZF1/3 downregulation; relapse cohorts (N=35) exhibited BATF upregulation, and MMRF CoMMpass (N=484) associated ETV4 upregulation with inferior outcomes, supporting enhancer compensation maintaining IRF4/MYC (teoh2024resistancetoimmunomodulatory pages 6-7). URL/date: Haematologica, Nov 2024, https://doi.org/10.3324/haematol.2024.285636.
- High‑throughput perturbation: 48‑line panel treated 3 days with 200 nM pomalidomide stratified IMiD sensitivity; EP300+IMiD combinations deepened IRF4/MYC repression yet AP‑1 maintained expression in resistant states (welsh2024transcriptionalheterogeneityovercomes pages 1-3). URL/date: Blood Cancer Discovery, Sep 2024, https://doi.org/10.1158/2643-3230.bcd-23-0062.
- Clinical activity benchmarks: Newer CELMoDs have achieved ~30–40% overall response rates (ORR) in IMiD‑refractory MM in clinical studies summarized by Davis et al. (indicating translational viability of further collapsing IRF4/MYC dependencies) (davis2024mycinhibitionpotentiates pages 1-3). URL/date: Clin Cancer Res, May/Jul 2024, https://doi.org/10.1158/1078-0432.ccr-24-0256.

Real‑World Implementations and Therapeutic Implications
- Standard of care and mechanism: IMiDs (lenalidomide, pomalidomide) and next‑generation CELMoDs degrade IKZF1/3 via CRBN, suppressing IRF4 and MYC. Real‑world resistance often reflects failure to extinguish IRF4/MYC due to enhancer‑level plasticity (welsh2024transcriptionalheterogeneityovercomes pages 19-20, davis2024mycinhibitionpotentiates pages 15-16, teoh2024resistancetoimmunomodulatory pages 6-7).
- Emerging strategies:
- Coactivator targeting: EP300/CBP catalytic inhibition combined with IMiDs to deepen IRF4/MYC suppression; attention to AP‑1 (BATF) activity as a bypass (welsh2024transcriptionalheterogeneityovercomes pages 1-3).
- Downstream oncogene targeting: MYC inhibition (e.g., MYCi975) synergizing with pomalidomide and boosting CD8+ T‑cell anti‑MM activity (davis2024mycinhibitionpotentiates pages 15-16).
- Post‑translational modulation: SUMO E1 inhibition (TAK‑981) reduces IRF4/MYC and re‑sensitizes to lenalidomide (davis2024mycinhibitionpotentiates pages 1-3).
- Lymphoma contexts: Recognition and testing for IRF4 rearrangements in LBCL can refine diagnosis and risk (co‑mutations in CARD11, CD79B, MYD88 support NF‑κB‑IRF4 pathway targeting) (ramiszaldivar2020distinctmolecularprofile pages 1-2).

Compliance with Target Identity and Ambiguity Checks
- Gene symbol/organism: All cited work pertains to human IRF4 ortholog functions or directly to human MM/DLBCL biology, matching UniProt Q15306 (Homo sapiens). Domain/family features (IRF family DBD+IAD; nuclear localization; partner‑dependent composite DNA recognition) are consistent across sources and align with UniProt annotations (lu2023regulatoryeffectsof pages 1-2, tatum2025structuralbiophysicaland pages 1-2, gabele2023unveilingirf4steeredregulation pages 17-19, tatum2025structuralbiophysicaland pages 20-23).

Embedded summary of 2023–2024 highlights
| Year | Source (journal; month) | URL / DOI | Focus Area | Key Findings | Relevance to IRF4 |
|---|---|---|---|---|---|
| 2024 | Blood Cancer Discovery (Sep 2024) | https://doi.org/10.1158/2643-3230.bcd-23-0062 (welsh2024transcriptionalheterogeneityovercomes pages 1-3) | IMiD + epigenetic combinations; resistance mechanisms | - EP300/IMiD combination more potently downregulates MYC and IRF4 and shows in vitro/in vivo synergy; - AP-1 factor BATF can maintain MYC/IRF4 and mediate resistance to enhancer-disrupting combos (experimental data across myeloma cell lines) | Demonstrates that targeting enhancer coactivators (EP300/CBP) can suppress the IRF4–MYC oncogenic module but resistance via AP-1/BATF can preserve IRF4 expression (welsh2024transcriptionalheterogeneityovercomes pages 1-3). |
| 2024 | Haematologica (Nov 2024) | https://doi.org/10.3324/haematol.2024.285636 (teoh2024resistancetoimmunomodulatory pages 6-7) | IMiD/CELMoD resistance biology in MM | - Reiterates CRBN→IKZF1/3→IRF4/MYC canonical axis; - Identifies compensatory factors (BATF, ETV4) upregulated at relapse that sustain IRF4/MYC; - Reports quantitative observations on Pom-treated cell lines (e.g., high viability in many resistant lines) | Provides mechanistic and quantitative evidence that maintained IRF4 (via IKZF-independent routes) underlies IMiD resistance and motivates combinations targeting enhancer machinery or compensatory TFs (teoh2024resistancetoimmunomodulatory pages 6-7). |
| 2024 | Clinical Cancer Research (May/Jul 2024) | https://doi.org/10.1158/1078-0432.ccr-24-0256 (davis2024mycinhibitionpotentiates pages 15-16) | MYC targeting to overcome IMiD resistance | - MYC inhibitor (MYCi975) shows potent anti‑MM activity in IMiD‑naïve and refractory primary samples; - MYCi975 synergizes with pomalidomide and enhances CD8+ T-cell cytotoxicity, re-sensitizing refractory samples | Supports downstream targeting of the IRF4–MYC axis (MYC inhibition) as a strategy to overcome IRF4-driven IMiD resistance and harness immune effector cells (davis2024mycinhibitionpotentiates pages 15-16). |
| 2023 | Frontiers in Immunology (Feb 2023) | https://doi.org/10.3389/fimmu.2023.1086803 (lu2023regulatoryeffectsof pages 1-2) | IRF4 regulation across tumor microenvironment and lymphocytes | - IRF4 is immune‑restricted and induced by antigen‑receptor/TCR signaling (not canonical IFN induction); - Central regulator of T/B cell differentiation, effector functions, and implicated in T‑cell exhaustion and TME immunosuppression | Places IRF4 as a context‑dependent transcriptional hub in lymphocytes and the tumor microenvironment, explaining why its modulation affects both anti‑tumor immunity and lymphoid malignancies (lu2023regulatoryeffectsof pages 1-2). |
| 2024 | Nature Reviews Endocrinology (May 2024) | https://doi.org/10.1038/s41574-024-00990-0 (representative review cited via related CD4/Th17 proteogenomics) (gabele2023unveilingirf4steeredregulation pages 17-19) | Transcriptional control of metabolism by IRFs (incl. IRF4) | - IRF family members, including IRF4, regulate chromatin and metabolic gene programs; - IRF4 participates in coupling transcriptional programs to cellular metabolism in immune cells | Highlights mechanistic link between IRF4 transcriptional programs and metabolic reprogramming in immune cells, relevant to Th17 differentiation and effector CD8+/Treg functions (gabele2023unveilingirf4steeredregulation pages 17-19). |
| 2023 | Cancer Gene Therapy (Mar 2023) | https://doi.org/10.1038/s41417-022-00450-9 (davis2024mycinhibitionpotentiates pages 1-3) | SUMOylation and IMiD sensitivity in MM | - SUMO‑E1 inhibition (TAK‑981) decreases IRF4 and c‑MYC levels and enhances lenalidomide sensitivity in resistant MM cell lines and primary samples; - Mechanism: reduced IRF4 transcription and enhanced IRF4 degradation | Demonstrates a non‑CRBN route to downregulate IRF4 (post‑translational/transcriptional) that can resensitize IMiD‑resistant myeloma—supports targeting IRF4 stability/regulation (davis2024mycinhibitionpotentiates pages 1-3). |
| 2020 | Blood (Jan 2020) | https://doi.org/10.1182/blood.2019002699 (ramiszaldivar2020distinctmolecularprofile pages 1-2) | IRF4 rearrangements in large B‑cell lymphoma (disease context) | - LBCL‑IRF4 cases show recurrent IRF4 alterations and frequent co‑alterations in NF‑κB pathway (CARD11, CD79B, MYD88) and distinct CNV patterns; - Defines molecular subset with prognostic implications | Establishes IRF4 rearrangement as a defining genetic lesion in a lymphoma subset, linking dysregulated IRF4 expression to lymphomagenesis and clinical stratification (ramiszaldivar2020distinctmolecularprofile pages 1-2). |
| 2023 | bioRxiv (Sep 2023) | https://doi.org/10.1101/2023.09.14.557376 (gabele2023unveilingirf4steeredregulation pages 17-19) | IRF4 DNA targeting and interactome in Th17/iTreg (mechanism) | - IRF4 is a weak solo DNA binder that relies on partners (PU.1 in B cells; AP‑1/BATF, AHR, FOXP3, IRF8 in T subsets); - Proteomic ChIP/Interactome reveals context‑specific partners and enhancer‑biased binding controlling lineage programs | Mechanistic demonstration that IRF4 target selection and transcriptional outcome are partner‑dependent (explains cell‑type specificity of IRF4 function and implications for therapeutic targeting) (gabele2023unveilingirf4steeredregulation pages 17-19). |

Table: Compact table summarizing key 2023–2024 findings on IRF4 (mechanisms, disease relevance, and therapeutic strategies) with citations to the evidence used.

References (with URLs and dates where available)
- Lu J et al. Regulatory effects of IRF4 on immune cells in the tumor microenvironment. Frontiers in Immunology. Feb 2023. https://doi.org/10.3389/fimmu.2023.1086803 (lu2023regulatoryeffectsof pages 1-2).
- Gabele A et al. Unveiling IRF4‑steered regulation of context‑dependent effector programs in Th17 and Treg cells. bioRxiv. Sep 2023. https://doi.org/10.1101/2023.09.14.557376 (gabele2023unveilingirf4steeredregulation pages 17-19, gabele2023unveilingirf4steeredregulation pages 12-14).
- Welsh SJ et al. Transcriptional heterogeneity overcomes super‑enhancer disrupting drug combinations in multiple myeloma. Blood Cancer Discovery. Sep 2024. https://doi.org/10.1158/2643-3230.bcd-23-0062 (welsh2024transcriptionalheterogeneityovercomes pages 1-3, welsh2024transcriptionalheterogeneityovercomes pages 19-20).
- Teoh PJ et al. Resistance to immunomodulatory drugs in multiple myeloma: the cereblon pathway and beyond. Haematologica. Nov 2024. https://doi.org/10.3324/haematol.2024.285636 (teoh2024resistancetoimmunomodulatory pages 6-7, teoh2024resistancetoimmunomodulatory pages 17-18, teoh2024resistancetoimmunomodulatory pages 12-14).
- Davis LN et al. MYC inhibition potentiates CD8+ T cells against multiple myeloma and overcomes immunomodulatory drug resistance. Clinical Cancer Research. May/Jul 2024. https://doi.org/10.1158/1078-0432.ccr-24-0256 (davis2024mycinhibitionpotentiates pages 15-16, davis2024mycinhibitionpotentiates pages 1-3).
- Du L et al. SUMOylation inhibition enhances multiple myeloma sensitivity to lenalidomide. Cancer Gene Therapy. Mar 2023. https://doi.org/10.1038/s41417-022-00450-9 (davis2024mycinhibitionpotentiates pages 1-3).
- Ramis‑Zaldivar JE et al. Distinct molecular profile of IRF4‑rearranged large B‑cell lymphoma. Blood. Jan 2020. https://doi.org/10.1182/blood.2019002699 (ramiszaldivar2020distinctmolecularprofile pages 1-2).
- Tatum NJ et al. Structural, biophysical and biological analysis of IRF4 DBD mutations. bioRxiv. Mar 2025. https://doi.org/10.1101/2025.03.12.642038 (tatum2025structuralbiophysicaland pages 1-2, tatum2025structuralbiophysicaland pages 20-23).

Notes on evidence strength: Several mechanistic and translational claims are supported by 2023–2024 peer‑reviewed studies (Frontiers Immunology 2023; Blood Cancer Discovery 2024; Clinical Cancer Research 2024; Haematologica 2024). Structural DBD and some mechanistic details rely on preprints (bioRxiv 2025) and should be interpreted with caution until peer review (tatum2025structuralbiophysicaland pages 1-2, tatum2025structuralbiophysicaland pages 20-23).

References

(lu2023regulatoryeffectsof pages 1-2): Jing Lu, Taotao Liang, Ping Li, and Qing-song Yin. Regulatory effects of irf4 on immune cells in the tumor microenvironment. Frontiers in Immunology, Feb 2023. URL: https://doi.org/10.3389/fimmu.2023.1086803, doi:10.3389/fimmu.2023.1086803. This article has 33 citations and is from a peer-reviewed journal.
(gabele2025elucidatingtherole pages 15-17): AMC Gabele. Elucidating the role of the transcription factor interferon regulatory factor 4 in differentiated t helper 17 and regulatory t cells. Unknown journal, 2025.
(gabele2025elucidatingtherolea pages 15-17): AMC Gabele. Elucidating the role of the transcription factor interferon regulatory factor 4 in differentiated t helper 17 and regulatory t cells. Unknown journal, 2025.
(tatum2025structuralbiophysicaland pages 1-2): Natalie J. Tatum, Rebecca Scott, Gina M. Doody, Ian Hickson, Claire E. Jennings, Mathew P. Martin, Reuben M. Tooze, Julie A. Tucker, Anita Wittner, Lan-Zhen Wang, Eleanor K. Wright, Stephen R. Wedge, and Martin E.M. Noble. Structural, biophysical and biological analysis and characterisation of irf4 dna-binding domain mutations associated with multiple myeloma. bioRxiv, Mar 2025. URL: https://doi.org/10.1101/2025.03.12.642038, doi:10.1101/2025.03.12.642038. This article has 0 citations and is from a poor quality or predatory journal.
(tatum2025structuralbiophysicaland pages 20-23): Natalie J. Tatum, Rebecca Scott, Gina M. Doody, Ian Hickson, Claire E. Jennings, Mathew P. Martin, Reuben M. Tooze, Julie A. Tucker, Anita Wittner, Lan-Zhen Wang, Eleanor K. Wright, Stephen R. Wedge, and Martin E.M. Noble. Structural, biophysical and biological analysis and characterisation of irf4 dna-binding domain mutations associated with multiple myeloma. bioRxiv, Mar 2025. URL: https://doi.org/10.1101/2025.03.12.642038, doi:10.1101/2025.03.12.642038. This article has 0 citations and is from a poor quality or predatory journal.
(gabele2023unveilingirf4steeredregulation pages 17-19): Anna Gabele, Maximilian Sprang, Mert Cihan, Sarah Dietzen, Matthias Klein, Gregory Harms, Tanja Ziesmann, Katrin Pape, Beatrice Wasser, David Gomez-Zepeda, Kathrin Braband, Michael Delacher, Niels Lemmermann, Stefan Bittner, Miguel A. Andrade-Navarro, Stefan Tenzer, Tobias Bopp, and Ute Distler. Unveiling irf4-steered regulation of context-dependent effector programs in th17 and treg cells. bioRxiv, Sep 2023. URL: https://doi.org/10.1101/2023.09.14.557376, doi:10.1101/2023.09.14.557376. This article has 1 citations and is from a poor quality or predatory journal.
(gabele2023unveilingirf4steeredregulation pages 12-14): Anna Gabele, Maximilian Sprang, Mert Cihan, Sarah Dietzen, Matthias Klein, Gregory Harms, Tanja Ziesmann, Katrin Pape, Beatrice Wasser, David Gomez-Zepeda, Kathrin Braband, Michael Delacher, Niels Lemmermann, Stefan Bittner, Miguel A. Andrade-Navarro, Stefan Tenzer, Tobias Bopp, and Ute Distler. Unveiling irf4-steered regulation of context-dependent effector programs in th17 and treg cells. bioRxiv, Sep 2023. URL: https://doi.org/10.1101/2023.09.14.557376, doi:10.1101/2023.09.14.557376. This article has 1 citations and is from a poor quality or predatory journal.
(davis2024mycinhibitionpotentiates pages 15-16): Lorraine N. Davis, Zachary J. Walker, Lauren T. Reiman, Sarah E. Parzych, Brett M. Stevens, Craig T. Jordan, Peter A. Forsberg, and Daniel W. Sherbenou. Myc inhibition potentiates cd8+ t cells against multiple myeloma and overcomes immunomodulatory drug resistance. Clinical cancer research : an official journal of the American Association for Cancer Research, 30:3023-3035, May 2024. URL: https://doi.org/10.1158/1078-0432.ccr-24-0256, doi:10.1158/1078-0432.ccr-24-0256. This article has 9 citations.
(welsh2024transcriptionalheterogeneityovercomes pages 1-3): Seth J. Welsh, Benjamin G. Barwick, Erin W. Meermeier, Daniel L. Riggs, Chang-Xin Shi, Yuan Xiao Zhu, Meaghen E. Sharik, Megan T. Du, Leslie D. Abrego Rocha, Victoria M. Garbitt, Caleb K. Stein, Joachim L. Petit, Nathalie Meurice, Yuliza Tafoya Alvarado, Rodrigo Fonseca, Kennedi T. Todd, Sochilt Brown, Zachery J. Hammond, Nicklus H. Cuc, Courtney Wittenberg, Camille Herzog, Anna V. Roschke, Yulia N. Demchenko, Wei-dong D. Chen, Peng Li, Wei Liao, Warren J. Leonard, Sagar Lonial, Nizar J. Bahlis, Paola Neri, Lawrence H. Boise, Marta Chesi, and P. Leif Bergsagel. Transcriptional heterogeneity overcomes super-enhancer disrupting drug combinations in multiple myeloma. Blood Cancer Discovery, 5:34-55, Sep 2024. URL: https://doi.org/10.1158/2643-3230.bcd-23-0062, doi:10.1158/2643-3230.bcd-23-0062. This article has 39 citations and is from a peer-reviewed journal.
(welsh2024transcriptionalheterogeneityovercomes pages 19-20): Seth J. Welsh, Benjamin G. Barwick, Erin W. Meermeier, Daniel L. Riggs, Chang-Xin Shi, Yuan Xiao Zhu, Meaghen E. Sharik, Megan T. Du, Leslie D. Abrego Rocha, Victoria M. Garbitt, Caleb K. Stein, Joachim L. Petit, Nathalie Meurice, Yuliza Tafoya Alvarado, Rodrigo Fonseca, Kennedi T. Todd, Sochilt Brown, Zachery J. Hammond, Nicklus H. Cuc, Courtney Wittenberg, Camille Herzog, Anna V. Roschke, Yulia N. Demchenko, Wei-dong D. Chen, Peng Li, Wei Liao, Warren J. Leonard, Sagar Lonial, Nizar J. Bahlis, Paola Neri, Lawrence H. Boise, Marta Chesi, and P. Leif Bergsagel. Transcriptional heterogeneity overcomes super-enhancer disrupting drug combinations in multiple myeloma. Blood Cancer Discovery, 5:34-55, Sep 2024. URL: https://doi.org/10.1158/2643-3230.bcd-23-0062, doi:10.1158/2643-3230.bcd-23-0062. This article has 39 citations and is from a peer-reviewed journal.
(teoh2024resistancetoimmunomodulatory pages 6-7): Phaik Ju Teoh, Mun Yee Koh, Constantine Mitsiades, Sarah Gooding, and Wee Joo Chng. Resistance to immunomodulatory drugs in multiple myeloma: the cereblon pathway and beyond. Haematologica, 110:1074-1091, Nov 2024. URL: https://doi.org/10.3324/haematol.2024.285636, doi:10.3324/haematol.2024.285636. This article has 3 citations.
(teoh2024resistancetoimmunomodulatory pages 12-14): Phaik Ju Teoh, Mun Yee Koh, Constantine Mitsiades, Sarah Gooding, and Wee Joo Chng. Resistance to immunomodulatory drugs in multiple myeloma: the cereblon pathway and beyond. Haematologica, 110:1074-1091, Nov 2024. URL: https://doi.org/10.3324/haematol.2024.285636, doi:10.3324/haematol.2024.285636. This article has 3 citations.
(ramiszaldivar2020distinctmolecularprofile pages 1-2): Joan Enric Ramis-Zaldivar, Blanca Gonzalez-Farré, Olga Balagué, Verónica Celis, Ferran Nadeu, Julia Salmerón-Villalobos, Mara Andrés, Idoia Martin-Guerrero, Marta Garrido-Pontnou, Ayman Gaafar, Mariona Suñol, Carmen Bárcena, Federico Garcia-Bragado, Maitane Andión, Daniel Azorín, Itziar Astigarraga, Maria Sagaseta de Ilurdoz, Constantino Sábado, Soledad Gallego, Jaime Verdú-Amorós, Rafael Fernandez-Delgado, Vanesa Perez, Gustavo Tapia, Anna Mozos, Montserrat Torrent, Palma Solano-Páez, Alfredo Rivas-Delgado, Ivan Dlouhy, Guillem Clot, Anna Enjuanes, Armando López-Guillermo, Pallavi Galera, Matthew J. Oberley, Alanna Maguire, Colleen Ramsower, Lisa M. Rimsza, Leticia Quintanilla-Martinez, Elaine S. Jaffe, Elías Campo, and Itziar Salaverria. Distinct molecular profile of irf4-rearranged large b-cell lymphoma. Blood, 135:274-286, Jan 2020. URL: https://doi.org/10.1182/blood.2019002699, doi:10.1182/blood.2019002699. This article has 128 citations and is from a highest quality peer-reviewed journal.
(davis2024mycinhibitionpotentiates pages 1-3): Lorraine N. Davis, Zachary J. Walker, Lauren T. Reiman, Sarah E. Parzych, Brett M. Stevens, Craig T. Jordan, Peter A. Forsberg, and Daniel W. Sherbenou. Myc inhibition potentiates cd8+ t cells against multiple myeloma and overcomes immunomodulatory drug resistance. Clinical cancer research : an official journal of the American Association for Cancer Research, 30:3023-3035, May 2024. URL: https://doi.org/10.1158/1078-0432.ccr-24-0256, doi:10.1158/1078-0432.ccr-24-0256. This article has 9 citations.
(teoh2024resistancetoimmunomodulatory pages 17-18): Phaik Ju Teoh, Mun Yee Koh, Constantine Mitsiades, Sarah Gooding, and Wee Joo Chng. Resistance to immunomodulatory drugs in multiple myeloma: the cereblon pathway and beyond. Haematologica, 110:1074-1091, Nov 2024. URL: https://doi.org/10.3324/haematol.2024.285636, doi:10.3324/haematol.2024.285636. This article has 3 citations.

Citations

tatum2025structuralbiophysicaland pages 20-23
lu2023regulatoryeffectsof pages 1-2
ramiszaldivar2020distinctmolecularprofile pages 1-2
welsh2024transcriptionalheterogeneityovercomes pages 1-3
teoh2024resistancetoimmunomodulatory pages 6-7
davis2024mycinhibitionpotentiates pages 15-16
davis2024mycinhibitionpotentiates pages 1-3
gabele2025elucidatingtherole pages 15-17
gabele2025elucidatingtherolea pages 15-17
tatum2025structuralbiophysicaland pages 1-2
welsh2024transcriptionalheterogeneityovercomes pages 19-20
teoh2024resistancetoimmunomodulatory pages 12-14
teoh2024resistancetoimmunomodulatory pages 17-18
https://doi.org/10.3389/fimmu.2023.1086803;
https://doi.org/10.1101/2025.03.12.642038.
https://doi.org/10.1101/2023.09.14.557376.
https://doi.org/10.1158/1078-0432.ccr-24-0256;
https://doi.org/10.1158/2643-3230.bcd-23-0062.
https://doi.org/10.3389/fimmu.2023.1086803.
https://doi.org/10.1158/2643-3230.bcd-23-0062;
https://doi.org/10.3324/haematol.2024.285636.
https://doi.org/10.1182/blood.2019002699.
https://doi.org/10.1158/1078-0432.ccr-24-0256.
https://doi.org/10.1038/s41417-022-00450-9.
https://doi.org/10.1158/2643-3230.bcd-23-0062
https://doi.org/10.3324/haematol.2024.285636
https://doi.org/10.1158/1078-0432.ccr-24-0256
https://doi.org/10.3389/fimmu.2023.1086803
https://doi.org/10.1038/s41574-024-00990-0
https://doi.org/10.1038/s41417-022-00450-9
https://doi.org/10.1182/blood.2019002699
https://doi.org/10.1101/2023.09.14.557376
https://doi.org/10.1101/2025.03.12.642038
https://doi.org/10.3389/fimmu.2023.1086803,
https://doi.org/10.1101/2025.03.12.642038,
https://doi.org/10.1101/2023.09.14.557376,
https://doi.org/10.1158/1078-0432.ccr-24-0256,
https://doi.org/10.1158/2643-3230.bcd-23-0062,
https://doi.org/10.3324/haematol.2024.285636,
https://doi.org/10.1182/blood.2019002699,

📄 View Raw YAML

id: Q15306
gene_symbol: IRF4
product_type: PROTEIN
status: DRAFT
taxon:
  id: NCBITaxon:9606
  label: Homo sapiens
description: IRF4 (Interferon Regulatory Factor 4, also known as MUM1/LSIRF/NF-EM5)
  is a lymphoid-restricted member of the IRF transcription factor family. Unlike most
  IRFs, IRF4 is not induced by interferons but is instead activated by antigen receptor
  signaling (TCR/BCR), IL-4, CD40, and LPS. IRF4 contains an N-terminal tryptophan-rich
  DNA-binding domain (DBD) recognizing ISRE-like GAAA motifs and a C-terminal IRF-associated
  domain (IAD) mediating homo/heterodimerization with partner transcription factors.
  IRF4 has intrinsically weak solo DNA-binding activity and acquires specificity through
  composite elements with partners such as PU.1/SPI-B at EICE motifs in B cells, and
  BATF/JUN at AICE motifs in T cells. IRF4 is essential for plasma cell differentiation,
  germinal center B cell fate decisions, and the differentiation of multiple T helper
  lineages (Th2, Th9, Th17) as well as effector CD8+ T cells. It also regulates dendritic
  cell and macrophage programs. IRF4 functions predominantly in the nucleus as a transcriptional
  activator. Dysregulation of IRF4 is implicated in multiple myeloma (where it is
  a lineage-survival oncogene), large B-cell lymphoma with IRF4 rearrangement, and
  combined immunodeficiency (IMD131). Genetic variants in IRF4 also influence human
  pigmentation through regulation of the TYR promoter in cooperation with MITF.
alternative_products:
- name: '1'
  id: Q15306-1
- name: '2'
  id: Q15306-2
  sequence_note: VSP_002755
existing_annotations:
- term:
    id: GO:0002376
    label: immune system process
  evidence_type: IBA
  original_reference_id: GO_REF:0000033
  review:
    summary: IRF4 is a lymphoid-restricted transcription factor that plays critical
      roles across multiple arms of the immune system, including B cell differentiation
      to plasma cells, T helper cell lineage commitment (Th2, Th9, Th17), effector
      CD8+ T cell differentiation, and dendritic cell and macrophage programs (PMID:12374808,
      deep research review).
    action: ACCEPT
    reason: This broad IBA annotation is accurate. IRF4 is expressed almost exclusively
      in immune cells and its functions are overwhelmingly immunological. The IBA
      is supported by phylogenetic inference across the IRF family and is consistent
      with extensive experimental evidence for IRF4 roles in both adaptive and innate
      immunity.
    supported_by:
    - reference_id: PMID:12374808
      supporting_text: Interferon regulatory factor (IRF)-4 is a lymphoid-restricted
        member of the interferon regulatory factor family of transcriptional regulators,
        whose deficiency leads to a profound impairment in the ability of mature CD4(+)
        T cells to produce cytokines.
- term:
    id: GO:0005634
    label: nucleus
  evidence_type: IBA
  original_reference_id: GO_REF:0000033
  review:
    summary: IRF4 is a transcription factor that functions in the nucleus, where it
      binds DNA at ISRE, EICE, and AICE composite elements to regulate target gene
      transcription. Nuclear localization is confirmed by UniProt annotation (ECO:0000269|PubMed:36917008)
      and structural studies of the DBD.
    action: ACCEPT
    reason: Nuclear localization is a core feature of IRF4 function as a DNA-binding
      transcription factor. The IBA annotation is consistent with multiple experimental
      lines of evidence including immunofluorescence and functional characterization
      of disease-causing variants that alter nuclear partitioning.
    supported_by:
    - reference_id: PMID:36917008
      supporting_text: Here, based on our investigation of a multigeneration family,
        we describe a novel autosomal dominant PAD caused by a pathogenic IRF4 variant
        affecting the IAD. All three patients in the family presented with low IgM,
        IgG, and IgA serum levels (diagnosed during childhood); low plasma cell counts;
        abnormal T cell subsets; and early hair graying.
- term:
    id: GO:0006357
    label: regulation of transcription by RNA polymerase II
  evidence_type: IBA
  original_reference_id: GO_REF:0000033
  review:
    summary: IRF4 is a DNA-binding transcription factor that regulates RNA polymerase
      II transcription of target genes including cytokines (IL-2, IL-4, IL-10, IL-13,
      IL-17), immunoglobulin genes, and genes involved in lymphocyte differentiation
      programs. It transactivates luciferase reporters driven by IL-2 and IL-4 promoters
      (PMID:12374808).
    action: ACCEPT
    reason: Regulation of Pol II transcription is the core biological process in which
      IRF4 participates. The IBA annotation is well-supported by the phylogeny of
      the IRF family and extensive experimental data from reporter assays, ChIP-seq,
      and genetic studies.
    supported_by:
    - reference_id: PMID:12374808
      supporting_text: Transient transfection assays indicate that IRF-4 can transactivate
        luciferase reporter constructs driven by either the human IL-2 or the human
        IL-4 promoter.
- term:
    id: GO:0000981
    label: DNA-binding transcription factor activity, RNA polymerase II-specific
  evidence_type: IBA
  original_reference_id: GO_REF:0000033
  review:
    summary: IRF4 is a sequence-specific DNA-binding transcription factor that regulates
      RNA polymerase II-dependent transcription. It binds ISRE motifs and composite
      elements (EICE, AICE) with partner TFs to activate target gene transcription.
      This is supported by crystal structures of the DBD bound to DNA, reporter assays,
      and ChIP-seq data.
    action: ACCEPT
    reason: This is the core molecular function of IRF4. The IBA annotation is consistent
      with extensive experimental evidence showing IRF4 functions as a DNA-binding
      transcription factor. Per GO-CAM TF annotation guidelines, this is the appropriate
      parent term for transcription factor activity.
    supported_by:
    - reference_id: PMID:12374808
      supporting_text: Transient transfection assays indicate that IRF-4 can transactivate
        luciferase reporter constructs driven by either the human IL-2 or the human
        IL-4 promoter.
    - reference_id: PMID:28473536
      supporting_text: By analysis of 542 human TFs with methylation-sensitive SELEX
        (systematic evolution of ligands by exponential enrichment), we found that
        there are also many TFs that prefer CpG-methylated sequences.
- term:
    id: GO:0000978
    label: RNA polymerase II cis-regulatory region sequence-specific DNA binding
  evidence_type: IBA
  original_reference_id: GO_REF:0000033
  review:
    summary: IRF4 binds sequence-specifically to cis-regulatory regions of Pol II-transcribed
      target genes, including ISRE motifs in MHC class I promoter, the immunoglobulin
      lambda light chain enhancer (with PU.1), and promoter regions of cytokine genes
      (IL-2, IL-4). The IRF4 DBD recognizes GAAA core motifs.
    action: ACCEPT
    reason: This accurately captures IRF4's DNA-binding specificity at cis-regulatory
      regions. The IBA annotation is supported by direct evidence from EMSA, reporter
      assays, and ChIP-seq studies. IRF4 binds cis-regulatory elements in a sequence-specific
      manner, recognizing ISRE, EICE, and AICE motifs.
    supported_by:
    - reference_id: PMID:12374808
      supporting_text: A detailed analysis of the effects of IRF-4 on the IL-4 promoter
        reveals that IRF-4 binds to a site adjacent to a functionally important NFAT
        binding element and that IRF-4 cooperates with NFATc1.
- term:
    id: GO:0000976
    label: transcription cis-regulatory region binding
  evidence_type: IEA
  original_reference_id: GO_REF:0000002
  review:
    summary: Electronic annotation based on InterPro domain IPR001346 (IRF DNA-binding
      domain). IRF4 does bind cis-regulatory regions through its conserved tryptophan
      pentad repeat DBD.
    action: ACCEPT
    reason: This IEA annotation is accurate but less specific than the IBA annotation
      for GO:0000978. The InterPro-based mapping correctly identifies cis-regulatory
      region binding as a function of the IRF DNA-binding domain. It is acceptable
      as a broader parent of the more specific IBA terms.
- term:
    id: GO:0000978
    label: RNA polymerase II cis-regulatory region sequence-specific DNA binding
  evidence_type: IEA
  original_reference_id: GO_REF:0000117
  review:
    summary: ARBA machine learning annotation for Pol II cis-regulatory region binding.
      Consistent with both the IBA annotation and direct experimental evidence.
    action: ACCEPT
    reason: This IEA annotation is a duplicate of the IBA annotation at GO:0000978
      and is correct. The ARBA-based electronic annotation independently supports
      the same molecular function.
- term:
    id: GO:0003677
    label: DNA binding
  evidence_type: IEA
  original_reference_id: GO_REF:0000043
  review:
    summary: General DNA binding annotation from UniProt keyword mapping. IRF4 does
      bind DNA through its N-terminal tryptophan pentad repeat domain (aa 21-129).
    action: MODIFY
    reason: While IRF4 unquestionably binds DNA, this term is too general and uninformative.
      More specific terms such as GO:0000978 (RNA polymerase II cis-regulatory region
      sequence-specific DNA binding) or GO:1990837 (sequence-specific double-stranded
      DNA binding) better capture IRF4's function.
    proposed_replacement_terms:
    - id: GO:0000978
      label: RNA polymerase II cis-regulatory region sequence-specific DNA binding
- term:
    id: GO:0003700
    label: DNA-binding transcription factor activity
  evidence_type: IEA
  original_reference_id: GO_REF:0000120
  review:
    summary: Combined automated annotation for DNA-binding transcription factor activity.
      Consistent with experimental evidence and more specific IBA/IDA annotations.
    action: ACCEPT
    reason: This is a correct annotation. While the more specific child term GO:0000981
      (RNA polymerase II-specific) is also annotated, this broader parent term from
      automated methods is not wrong and is acceptable as a general descriptor.
- term:
    id: GO:0005634
    label: nucleus
  evidence_type: IEA
  original_reference_id: GO_REF:0000044
  review:
    summary: Electronic annotation for nuclear localization based on UniProt subcellular
      location vocabulary. Consistent with IRF4 being a nuclear transcription factor.
    action: ACCEPT
    reason: Correct annotation. IRF4 is primarily nuclear, consistent with its function
      as a DNA-binding transcription factor. This is supported by both IBA and IMP
      annotations at the same term.
- term:
    id: GO:0005737
    label: cytoplasm
  evidence_type: IEA
  original_reference_id: GO_REF:0000044
  review:
    summary: Electronic annotation for cytoplasmic localization based on UniProt subcellular
      location. UniProt reports cytoplasmic localization based on PMID:36917008.
    action: ACCEPT
    reason: IRF4 is found in both nucleus and cytoplasm. The cytoplasmic pool likely
      represents either newly synthesized protein prior to nuclear import or a regulated
      cytoplasmic retention mechanism. This is consistent with the IMP annotation
      at the same term from PMID:36917008.
- term:
    id: GO:0006355
    label: regulation of DNA-templated transcription
  evidence_type: IEA
  original_reference_id: GO_REF:0000002
  review:
    summary: InterPro-based annotation for regulation of DNA-templated transcription,
      based on IRF domains IPR019471 and IPR019817.
    action: ACCEPT
    reason: This is a correct but general annotation. IRF4 is a transcription factor
      and regulation of DNA-templated transcription is its core biological process.
      While more specific terms exist (e.g., GO:0006357 regulation of transcription
      by RNA polymerase II), this broader IEA annotation from InterPro mapping is
      not wrong.
- term:
    id: GO:0045944
    label: positive regulation of transcription by RNA polymerase II
  evidence_type: IEA
  original_reference_id: GO_REF:0000117
  review:
    summary: ARBA machine learning annotation for positive regulation of Pol II transcription.
      IRF4 primarily acts as a transcriptional activator.
    action: ACCEPT
    reason: This is correct and consistent with the IDA annotation at the same term
      (PMID:12374808). IRF4 functions predominantly as a transcriptional activator,
      demonstrated by reporter assays showing transactivation of IL-2 and IL-4 promoter
      constructs.
- term:
    id: GO:0051240
    label: positive regulation of multicellular organismal process
  evidence_type: IEA
  original_reference_id: GO_REF:0000117
  review:
    summary: ARBA-based annotation for positive regulation of multicellular organismal
      process.
    action: MARK_AS_OVER_ANNOTATED
    reason: This term is extremely broad and uninformative. While IRF4 does participate
      in processes that positively regulate multicellular organismal processes (e.g.,
      immune cell differentiation), this annotation is too vague to be useful. More
      specific terms like regulation of T-helper cell differentiation or plasma cell
      differentiation are far more informative.
- term:
    id: GO:0005515
    label: protein binding
  evidence_type: IPI
  original_reference_id: PMID:21903422
  review:
    summary: This annotation derives from a large-scale innate immunity interactome
      study (HI5) that mapped protein interactions regulating type I interferon production.
      IRF4 (as bait or prey) was found to interact with IKBKAP (ELP1), IRAK1, TLK2,
      and YTHDC2 by affinity purification-mass spectrometry (PMID:21903422). The paper
      notes IKBKAP interacts with IRF4 and negatively regulates HSV-induced IFN production.
    action: MARK_AS_OVER_ANNOTATED
    reason: While the physical interactions detected in this high-throughput screen
      are plausible, generic "protein binding" is uninformative. Some of these interactions
      (e.g., with ELP1/IKBKAP) are from a large-scale screen and may not reflect core
      IRF4 biology. The functionally important interactions of IRF4 are with PU.1/SPI1,
      BATF/JUN, SPIB, and DEF6, which are better described by more specific binding
      terms.
    supported_by:
    - reference_id: PMID:21903422
      supporting_text: IKBKAP interacts with IRF4 and negatively regulates HSV-induced
        IFN production.
- term:
    id: GO:0005515
    label: protein binding
  evidence_type: IPI
  original_reference_id: PMID:32296183
  review:
    summary: This annotation derives from the HuRI (Human Reference Interactome) project,
      a systematic binary interactome mapping using yeast two-hybrid. IRF4 interactions
      with GIPC2 and TSEN54 were detected.
    action: MARK_AS_OVER_ANNOTATED
    reason: Generic "protein binding" from a high-throughput yeast two-hybrid screen
      is uninformative. The detected interactions (GIPC2, TSEN54) do not have clear
      functional relevance to IRF4's known biology as a transcription factor in immune
      cells. These may represent technical artifacts or biologically minor interactions.
    supported_by:
    - reference_id: PMID:32296183
      supporting_text: Here we present a human 'all-by-all' reference interactome
        map of human binary protein interactions, or 'HuRI'. With approximately 53,000
        protein-protein interactions, HuRI has approximately four times as many such
        interactions as there are high-quality curated interactions from small-scale
        studies.
- term:
    id: GO:0000786
    label: nucleosome
  evidence_type: IEA
  original_reference_id: GO_REF:0000107
  review:
    summary: Ensembl Compara-transferred annotation from mouse IRF4 (Q64287) suggesting
      IRF4 is part of nucleosomes.
    action: MARK_AS_OVER_ANNOTATED
    reason: While IRF4 binds chromatin and may interact with nucleosomal DNA in the
      context of chromatin remodeling, being annotated as "part_of nucleosome" is
      misleading. IRF4 is not a histone or structural component of the nucleosome.
      It is a transcription factor that binds to cis-regulatory elements, some of
      which may be nucleosomal. The chromatin (GO:0000785) annotation is more appropriate.
- term:
    id: GO:0000987
    label: cis-regulatory region sequence-specific DNA binding
  evidence_type: IEA
  original_reference_id: GO_REF:0000107
  review:
    summary: Ensembl Compara-transferred annotation from mouse IRF4 for cis-regulatory
      region sequence-specific DNA binding.
    action: ACCEPT
    reason: This is correct and consistent with other annotations. IRF4 binds cis-regulatory
      regions in a sequence-specific manner at ISRE, EICE, and AICE motifs. This is
      a parent term of GO:0000978 which is also annotated.
- term:
    id: GO:0003713
    label: transcription coactivator activity
  evidence_type: IEA
  original_reference_id: GO_REF:0000107
  review:
    summary: Ensembl Compara-transferred annotation suggesting IRF4 has transcription
      coactivator activity, based on mouse ortholog data.
    action: MODIFY
    reason: IRF4 is primarily a DNA-binding transcription factor, not a coactivator.
      A coactivator does not directly bind DNA but enhances transcription through
      interaction with DNA-binding TFs. IRF4 directly binds DNA at ISRE/EICE/AICE
      elements. The appropriate term is GO:0001228 (DNA-binding transcription activator
      activity, RNA polymerase II-specific), which is already annotated with experimental
      evidence. This annotation likely derives from mouse studies where IRF4 cooperates
      with other TFs, but cooperation does not make it a coactivator.
    proposed_replacement_terms:
    - id: GO:0001228
      label: DNA-binding transcription activator activity, RNA polymerase II-specific
- term:
    id: GO:0042832
    label: defense response to protozoan
  evidence_type: IEA
  original_reference_id: GO_REF:0000107
  review:
    summary: Ensembl Compara-transferred annotation from mouse IRF4 for defense response
      to protozoan. Mouse Irf4 is required for immune defense against Leishmania and
      Toxoplasma.
    action: KEEP_AS_NON_CORE
    reason: While IRF4 is required for effective immune responses including those
      against protozoan parasites (primarily through its role in T cell differentiation
      and cytokine regulation), defense response to protozoan is not a core function
      of IRF4. It is a downstream consequence of IRF4's role in immune cell differentiation.
      The annotation is based on mouse ortholog data where IRF4 knockout mice show
      susceptibility to protozoan infection.
- term:
    id: GO:0043565
    label: sequence-specific DNA binding
  evidence_type: IEA
  original_reference_id: GO_REF:0000107
  review:
    summary: Ensembl Compara-transferred annotation for sequence-specific DNA binding
      from mouse IRF4.
    action: ACCEPT
    reason: This is correct. IRF4 binds DNA in a sequence-specific manner through
      its tryptophan pentad repeat DBD, recognizing GAAA core motifs. This is a parent
      term of the more specific cis-regulatory region binding terms also annotated.
- term:
    id: GO:0045893
    label: positive regulation of DNA-templated transcription
  evidence_type: IEA
  original_reference_id: GO_REF:0000107
  review:
    summary: Ensembl Compara-transferred annotation for positive regulation of DNA-templated
      transcription.
    action: ACCEPT
    reason: Correct and consistent with the IDA annotation at the same term from PMID:12374808.
      IRF4 functions primarily as a transcriptional activator, as demonstrated by
      reporter assays with IL-2 and IL-4 promoter constructs.
- term:
    id: GO:0072540
    label: T-helper 17 cell lineage commitment
  evidence_type: IEA
  original_reference_id: GO_REF:0000107
  review:
    summary: Ensembl Compara-transferred annotation from mouse IRF4 for Th17 cell
      lineage commitment. Mouse studies show IRF4 is required for Th17 differentiation,
      binding and promoting Il17a/f, Il21, and Rorc expression.
    action: KEEP_AS_NON_CORE
    reason: IRF4 is indeed essential for Th17 differentiation in mouse, and this role
      is conserved in human. However, Th17 lineage commitment is one of several immune
      cell differentiation programs regulated by IRF4 (also Th2, Th9, effector CD8+,
      plasma cells). This is a legitimate but non-core annotation representing one
      specific downstream function. The annotation is based on transfer from well-established
      mouse experimental data.
- term:
    id: GO:0120162
    label: positive regulation of cold-induced thermogenesis
  evidence_type: IEA
  original_reference_id: GO_REF:0000107
  review:
    summary: Ensembl Compara-transferred annotation from mouse IRF4 for positive regulation
      of cold-induced thermogenesis. This derives from a mouse study (PMID:24995979)
      showing IRF4 promotes thermogenic gene expression in brown adipose tissue.
    action: KEEP_AS_NON_CORE
    reason: This annotation reflects a non-immune role of IRF4 in thermogenesis/adipose
      biology. While interesting, this is clearly a non-core function given that IRF4
      is predominantly expressed in and functionally characterized in lymphoid cells.
      The human relevance of this mouse finding is uncertain.
- term:
    id: GO:0005654
    label: nucleoplasm
  evidence_type: IDA
  original_reference_id: GO_REF:0000052
  review:
    summary: IDA annotation based on immunofluorescence data curated by the Human
      Protein Atlas (HPA). IRF4 is detected in the nucleoplasm by immunofluorescence
      in relevant cell types.
    action: ACCEPT
    reason: Nucleoplasm localization is expected and correct for a transcription factor.
      The IDA evidence from immunofluorescence is reliable for localization. IRF4
      functions in the nucleoplasm where it binds DNA and regulates transcription.
- term:
    id: GO:0001228
    label: DNA-binding transcription activator activity, RNA polymerase II-specific
  evidence_type: IMP
  original_reference_id: PMID:36662884
  review:
    summary: IMP annotation based on Fornes et al. (2023) Sci Immunol, which characterized
      IRF4 T95R variant in IMD131 patients. The T95R mutant gains neomorphic DNA binding
      to GATA-containing sequences not recognized by wildtype, while showing decreased
      transcription activation from canonical ISRE reporter constructs. This demonstrates
      that wildtype IRF4 normally has DNA-binding transcription activator activity.
    action: ACCEPT
    reason: The mutant phenotype analysis confirms that wildtype IRF4 functions as
      a DNA-binding transcription activator. Loss of this activity in disease-causing
      variants directly supports the annotation. This is the most specific appropriate
      MF term per GO-CAM TF guidelines.
    supported_by:
    - reference_id: PMID:36662884
      supporting_text: Interferon regulatory factor 4 (IRF4) is a transcription factor
        (TF) and key regulator of immune cell development and function. We report
        a recurrent heterozygous mutation in IRF4, p.T95R, causing an autosomal dominant
        combined immunodeficiency (CID) in seven patients from six unrelated families.
- term:
    id: GO:0001228
    label: DNA-binding transcription activator activity, RNA polymerase II-specific
  evidence_type: IMP
  original_reference_id: PMID:36917008
  review:
    summary: IMP annotation based on Thouenon et al. (2023) J Exp Med, characterizing
      the IRF4 F359L neomorphic variant in IMD131 patients. The F359L variant shows
      loss of DNA-binding transcription activator activity, confirming this is the
      normal function of wildtype IRF4.
    action: ACCEPT
    reason: Another disease variant study that confirms IRF4's transcriptional activator
      function through loss-of-function analysis. The F359L mutation in the IAD abolishes
      activator activity.
    supported_by:
    - reference_id: PMID:36917008
      supporting_text: The mutant IRF4 failed to efficiently regulate the transcriptional
        activity of interferon-stimulated response elements (ISREs). Rapid immunoprecipitation
        mass spectrometry of endogenous proteins indicated that the mutant and wildtype
        IRF4 proteins differed with regard to their respective sets of binding partners.
- term:
    id: GO:0005634
    label: nucleus
  evidence_type: IMP
  original_reference_id: PMID:36917008
  review:
    summary: IMP annotation for nuclear localization from the Thouenon et al. (2023)
      study. The F359L variant shows no effect on subcellular location, indicating
      that wildtype (and mutant) IRF4 localizes to the nucleus.
    action: ACCEPT
    reason: Nuclear localization is well-established for IRF4 and confirmed by this
      IMP study. This is expected for a DNA-binding transcription factor.
    supported_by:
    - reference_id: PMID:36917008
      supporting_text: The IRF4 F359L and IRF4 WT proteins were similar with regard
        to their subcellular localization in the cytoplasm and the nucleus
- term:
    id: GO:0005737
    label: cytoplasm
  evidence_type: IMP
  original_reference_id: PMID:36917008
  review:
    summary: IMP annotation for cytoplasmic localization from the Thouenon et al.
      (2023) study. IRF4 is present in cytoplasm as well as nucleus.
    action: ACCEPT
    reason: Cytoplasmic localization is confirmed by experimental evidence. IRF4 is
      likely present in the cytoplasm as a pre-nuclear pool or under conditions of
      cytoplasmic retention. This is consistent with UniProt subcellular localization
      annotation.
    supported_by:
    - reference_id: PMID:36917008
      supporting_text: The IRF4 F359L and IRF4 WT proteins were similar with regard
        to their subcellular localization in the cytoplasm and the nucleus
- term:
    id: GO:0001228
    label: DNA-binding transcription activator activity, RNA polymerase II-specific
  evidence_type: IMP
  original_reference_id: PMID:29537367
  review:
    summary: IMP annotation from Guerin et al. (2018) eLife, characterizing the IRF4
      R98W variant in a family with Whipple's disease and IRF4 haploinsufficiency.
      The R98W mutation causes loss of DNA-binding transcription activator activity,
      and RC98-99AA double mutant also loses this activity.
    action: ACCEPT
    reason: The loss-of-function analysis of the R98W disease variant provides direct
      evidence that wildtype IRF4 has DNA-binding transcription activator activity.
      The R98 residue is within the IRF DBD (aa 21-129) and is critical for DNA contact.
    supported_by:
    - reference_id: PMID:29537367
      supporting_text: We found that R98W was loss-of-function, modified the transcriptome
        of heterozygous leukocytes following Tw stimulation, and was not dominant-negative.
        We also found that only six of the other 153 known non-synonymous IRF4 variants
        were loss-of-function.
- term:
    id: GO:0005654
    label: nucleoplasm
  evidence_type: TAS
  original_reference_id: Reactome:R-HSA-9907145
  review:
    summary: TAS annotation from Reactome pathway R-HSA-9907145 (IRF4 binds the TYR
      promoter), placing IRF4 in the nucleoplasm where it binds the tyrosinase promoter
      in cooperation with MITF.
    action: ACCEPT
    reason: Correct localization for a transcription factor binding a target promoter.
      The Reactome pathway describes IRF4's role in pigmentation gene regulation.
- term:
    id: GO:0005654
    label: nucleoplasm
  evidence_type: TAS
  original_reference_id: Reactome:R-HSA-9907147
  review:
    summary: TAS annotation from Reactome pathway R-HSA-9907147 (MITF-M-dependent
      IRF4 gene expression), placing IRF4 in the nucleoplasm.
    action: ACCEPT
    reason: Correct annotation. IRF4 is expressed and functions in the nucleoplasm.
- term:
    id: GO:0005515
    label: protein binding
  evidence_type: IPI
  original_reference_id: PMID:33951726
  review:
    summary: IPI annotation from Le Coz et al. (2021) J Exp Med, demonstrating that
      IRF4 directly interacts with PU.1 (SPI1). PU.1 mutations in agammaglobulinemia
      patients constrain chromatin accessibility. The interaction between PU.1 and
      IRF4 at EICE composite elements is a well-characterized functional partnership
      essential for B cell gene regulation.
    action: MODIFY
    reason: The interaction between IRF4 and PU.1/SPI1 is functionally critical and
      well-characterized, but "protein binding" is too vague. IRF4-PU.1 interaction
      at EICE elements is a core mechanism for IRF4 target gene selection in B cells.
      A more specific term describing transcription factor binding or DNA-binding
      transcription factor binding would be more informative.
    proposed_replacement_terms:
    - id: GO:0140297
      label: DNA-binding transcription factor binding
    supported_by:
    - reference_id: PMID:33951726
      supporting_text: Consistent with intact PEST domains, all three proteins coimmunoprecipitated
        with IRF4 and IRF8 (Fig. S5 E).
- term:
    id: GO:1990837
    label: sequence-specific double-stranded DNA binding
  evidence_type: IDA
  original_reference_id: PMID:28473536
  review:
    summary: IDA annotation from Yin et al. (2017) Science, a systematic analysis
      of DNA binding specificities of 542 human TFs using SELEX. IRF4 DNA binding
      specificity was characterized in this high-throughput but rigorous assay.
    action: ACCEPT
    reason: This annotation is well-supported. The SELEX-based analysis provided direct
      experimental evidence for sequence-specific double-stranded DNA binding by IRF4.
      The study identified binding motifs for hundreds of TFs using purified proteins,
      providing direct biochemical evidence of IRF4's DNA binding activity.
    supported_by:
    - reference_id: PMID:28473536
      supporting_text: By analysis of 542 human TFs with methylation-sensitive SELEX
        (systematic evolution of ligands by exponential enrichment), we found that
        there are also many TFs that prefer CpG-methylated sequences.
- term:
    id: GO:0000785
    label: chromatin
  evidence_type: ISA
  original_reference_id: GO_REF:0000113
  review:
    summary: ISA annotation from TFClass database (tfclass:3.5.3), placing IRF4 at
      chromatin. As a DNA-binding transcription factor, IRF4 associates with chromatin
      at its target gene regulatory regions.
    action: ACCEPT
    reason: Correct annotation. IRF4 binds chromatin at cis-regulatory elements of
      target genes. The TFClass-based annotation appropriately recognizes that sequence-specific
      DNA-binding TFs are located at chromatin.
- term:
    id: GO:0000981
    label: DNA-binding transcription factor activity, RNA polymerase II-specific
  evidence_type: ISA
  original_reference_id: GO_REF:0000113
  review:
    summary: 'ISA annotation from TFClass database classifying IRF4 as a sequence-specific
      DNA-binding transcription factor (class 3.5.3 - Tryptophan cluster factors:
      IRF subfamily).'
    action: ACCEPT
    reason: Correct annotation consistent with IRF4's classification as an IRF family
      transcription factor. This duplicates the IBA annotation but provides independent
      evidence from the TFClass classification system.
- term:
    id: GO:0120162
    label: positive regulation of cold-induced thermogenesis
  evidence_type: ISS
  original_reference_id: PMID:24995979
  review:
    summary: ISS annotation based on mouse IRF4 ortholog (Q64287) data from PMID:24995979,
      transferred by YuBioLab. Mouse IRF4 promotes thermogenic gene expression in
      brown adipose tissue.
    action: KEEP_AS_NON_CORE
    reason: This is the same annotation as the IEA Ensembl Compara transfer. While
      the mouse data supports a role for IRF4 in thermogenesis, this is clearly a
      non-core function for a protein primarily characterized as an immune system
      transcription factor. The human relevance is uncertain.
    supported_by:
    - reference_id: PMID:24995979
      supporting_text: IRF4 is induced by cold and cAMP in adipocytes and is sufficient
        to promote increased thermogenic gene expression, energy expenditure, and
        cold tolerance.
- term:
    id: GO:0000978
    label: RNA polymerase II cis-regulatory region sequence-specific DNA binding
  evidence_type: IDA
  original_reference_id: PMID:12374808
  review:
    summary: IDA annotation from Hu et al. (2002) showing IRF4 binds to a specific
      site in the IL-4 promoter adjacent to an NFAT binding element, as demonstrated
      by EMSA and reporter assays in Jurkat T cells.
    action: ACCEPT
    reason: Direct experimental evidence from EMSA showing IRF4 binds a specific DNA
      site in the IL-4 promoter. This is a core molecular function supported by detailed
      promoter analysis.
    supported_by:
    - reference_id: PMID:12374808
      supporting_text: A detailed analysis of the effects of IRF-4 on the IL-4 promoter
        reveals that IRF-4 binds to a site adjacent to a functionally important NFAT
        binding element and that IRF-4 cooperates with NFATc1.
- term:
    id: GO:0001228
    label: DNA-binding transcription activator activity, RNA polymerase II-specific
  evidence_type: IDA
  original_reference_id: PMID:12374808
  review:
    summary: IDA annotation from Hu et al. (2002) showing IRF4 transactivates luciferase
      reporter constructs driven by IL-2 and IL-4 promoters in Jurkat T cells. Stable
      IRF4 expression enhanced IL-2 synthesis and enabled production of IL-4, IL-10,
      and IL-13.
    action: ACCEPT
    reason: Direct evidence that IRF4 functions as a transcriptional activator. This
      is the most specific appropriate MF term per GO-CAM TF annotation guidelines.
      The reporter assays directly demonstrate transcription activator activity.
    supported_by:
    - reference_id: PMID:12374808
      supporting_text: Transient transfection assays indicate that IRF-4 can transactivate
        luciferase reporter constructs driven by either the human IL-2 or the human
        IL-4 promoter.
- term:
    id: GO:0045944
    label: positive regulation of transcription by RNA polymerase II
  evidence_type: IDA
  original_reference_id: PMID:12374808
  review:
    summary: IDA annotation from Hu et al. (2002) demonstrating that IRF4 positively
      regulates Pol II transcription of cytokine genes in T cells, as shown by reporter
      assays and endogenous cytokine production measurements.
    action: ACCEPT
    reason: Direct experimental evidence showing IRF4 activates transcription from
      IL-2 and IL-4 promoters. This biological process annotation is the appropriate
      complement to the MF annotation for transcription activator activity.
    supported_by:
    - reference_id: PMID:12374808
      supporting_text: We demonstrate that stable expression of IRF-4 in Jurkat T
        cells not only leads to a strong enhancement in the synthesis of interleukin
        (IL)-2, but also enables these cells to start producing considerable amounts
        of IL-4, IL-10, and IL-13.
- term:
    id: GO:0016020
    label: membrane
  evidence_type: HDA
  original_reference_id: PMID:19946888
  review:
    summary: HDA annotation from Ghosh et al. (2010), a proteomics study defining
      the membrane proteome of NK cells (YTS cell line). IRF4 was identified among
      1843 proteins in membrane fractions.
    action: MARK_AS_OVER_ANNOTATED
    reason: IRF4 is a nuclear transcription factor and not a membrane protein. Its
      detection in membrane fractions in this proteomics study likely represents contamination
      from nuclear/cytoplasmic fractions or transient association during cell lysis.
      The study itself notes that approximately 60% of identified proteins were not
      predicted membrane proteins. This annotation does not reflect a genuine biological
      function or localization of IRF4.
    supported_by:
    - reference_id: PMID:19946888
      supporting_text: The remaining species were largely involved in cellular processes
        and molecular functions that could be predicted to be transiently associated
        with membranes.
- term:
    id: GO:0005829
    label: cytosol
  evidence_type: TAS
  original_reference_id: Reactome:R-HSA-1015702
  review:
    summary: TAS annotation from Reactome pathway R-HSA-1015702 (Expression of IFN-induced
      genes), placing IRF4 in the cytosol. This represents a Reactome model where
      IRF4 is produced in the cytosol before translocation to the nucleus.
    action: ACCEPT
    reason: IRF4 is synthesized in the cytosol and can be found there. While its primary
      functional location is the nucleus, cytosolic localization is supported by UniProt
      and the Reactome pathway models. The cytosol annotation from Reactome likely
      represents the newly synthesized protein pool.
- term:
    id: GO:0005829
    label: cytosol
  evidence_type: TAS
  original_reference_id: Reactome:R-HSA-1031716
  review:
    summary: TAS annotation from Reactome pathway R-HSA-1031716 (Expression of IFNG-stimulated
      genes).
    action: ACCEPT
    reason: Duplicate cytosol annotation from a different Reactome pathway. Acceptable
      as IRF4 is present in the cytosol.
- term:
    id: GO:0005829
    label: cytosol
  evidence_type: TAS
  original_reference_id: Reactome:R-HSA-6790041
  review:
    summary: TAS annotation from Reactome pathway R-HSA-6790041 (Expression of STAT3-upregulated
      cytosolic proteins).
    action: ACCEPT
    reason: Duplicate cytosol annotation from a Reactome pathway modeling STAT3-dependent
      IRF4 expression. Acceptable as IRF4 is present in the cytosol.
- term:
    id: GO:0005829
    label: cytosol
  evidence_type: TAS
  original_reference_id: Reactome:R-HSA-9851117
  review:
    summary: TAS annotation from Reactome pathway R-HSA-9851117 (NPM1-ALK- and p-STAT3-dependent
      IRF4 gene expression).
    action: ACCEPT
    reason: Duplicate cytosol annotation from a Reactome pathway modeling ALK-STAT3-dependent
      IRF4 expression in lymphoma contexts.
- term:
    id: GO:0003700
    label: DNA-binding transcription factor activity
  evidence_type: ISS
  original_reference_id: GO_REF:0000024
  review:
    summary: Manual transfer from mouse IRF4 (Q64287) for DNA-binding transcription
      factor activity.
    action: ACCEPT
    reason: Correct annotation. IRF4 is a DNA-binding transcription factor in both
      mouse and human. This broader term is a parent of the more specific GO:0000981
      and GO:0001228 that are also annotated with stronger evidence.
- term:
    id: GO:0042832
    label: defense response to protozoan
  evidence_type: ISS
  original_reference_id: GO_REF:0000024
  review:
    summary: Manual transfer from mouse IRF4 for defense response to protozoan. Mouse
      Irf4-/- mice show impaired immune responses to Leishmania and Toxoplasma.
    action: KEEP_AS_NON_CORE
    reason: Same annotation as the IEA Ensembl Compara transfer. IRF4 is required
      for effective immune responses against protozoan parasites through its role
      in T cell differentiation, but this is a downstream consequence rather than
      a core function.
- term:
    id: GO:0043565
    label: sequence-specific DNA binding
  evidence_type: ISS
  original_reference_id: GO_REF:0000024
  review:
    summary: Manual transfer from mouse IRF4 for sequence-specific DNA binding.
    action: ACCEPT
    reason: Correct and consistent with experimental evidence. IRF4 binds DNA in a
      sequence-specific manner through its tryptophan pentad repeat domain.
- term:
    id: GO:0072540
    label: T-helper 17 cell lineage commitment
  evidence_type: ISS
  original_reference_id: GO_REF:0000024
  review:
    summary: Manual transfer from mouse IRF4 for Th17 cell lineage commitment. Mouse
      Irf4-/- mice fail to develop Th17 cells.
    action: KEEP_AS_NON_CORE
    reason: Same annotation as the IEA transfer. IRF4 is essential for Th17 differentiation,
      but this is one of several immune cell differentiation programs regulated by
      IRF4 and is a non-core annotation.
- term:
    id: GO:0005634
    label: nucleus
  evidence_type: IC
  original_reference_id: PMID:12374808
  review:
    summary: Curator inference that IRF4 is nuclear, based on evidence that it functions
      as a DNA-binding transcription factor (GO:0003700). Inferred from PMID:12374808
      showing IRF4 transactivates promoter-reporter constructs and binds DNA.
    action: ACCEPT
    reason: Logical inference that a DNA-binding transcription factor localizes to
      the nucleus. This is confirmed by direct evidence (IDA from HPA, IMP from PMID:36917008).
    supported_by:
    - reference_id: PMID:12374808
      supporting_text: Transient transfection assays indicate that IRF-4 can transactivate
        luciferase reporter constructs driven by either the human IL-2 or the human
        IL-4 promoter.
- term:
    id: GO:0032733
    label: positive regulation of interleukin-10 production
  evidence_type: IDA
  original_reference_id: PMID:12374808
  review:
    summary: Hu et al. (2002) showed that stable expression of IRF4 in Jurkat T cells
      enabled production of IL-10. IRF4 deficiency in mouse T cells profoundly impairs
      cytokine production.
    action: KEEP_AS_NON_CORE
    reason: This is a legitimate downstream effect of IRF4 transcriptional activity
      in T cells. However, positive regulation of IL-10 production is a downstream
      consequence of IRF4's transcription factor activity rather than a core function.
      IRF4 likely activates IL-10 transcription indirectly through its effects on
      T cell differentiation programs.
    supported_by:
    - reference_id: PMID:12374808
      supporting_text: We demonstrate that stable expression of IRF-4 in Jurkat T
        cells not only leads to a strong enhancement in the synthesis of interleukin
        (IL)-2, but also enables these cells to start producing considerable amounts
        of IL-4, IL-10, and IL-13.
- term:
    id: GO:0032736
    label: positive regulation of interleukin-13 production
  evidence_type: IDA
  original_reference_id: PMID:12374808
  review:
    summary: Hu et al. (2002) showed that stable expression of IRF4 in Jurkat T cells
      enabled production of IL-13.
    action: KEEP_AS_NON_CORE
    reason: Legitimate downstream effect of IRF4 transcriptional activity. IL-13 production
      is enabled by IRF4 in the context of Th2 differentiation. This represents a
      specific downstream output of IRF4's transcription factor activity rather than
      a core molecular function.
    supported_by:
    - reference_id: PMID:12374808
      supporting_text: We demonstrate that stable expression of IRF-4 in Jurkat T
        cells not only leads to a strong enhancement in the synthesis of interleukin
        (IL)-2, but also enables these cells to start producing considerable amounts
        of IL-4, IL-10, and IL-13.
- term:
    id: GO:0032743
    label: positive regulation of interleukin-2 production
  evidence_type: IDA
  original_reference_id: PMID:12374808
  review:
    summary: Hu et al. (2002) showed that stable IRF4 expression in Jurkat T cells
      strongly enhanced IL-2 synthesis. IRF4 transactivates luciferase reporters driven
      by the human IL-2 promoter.
    action: KEEP_AS_NON_CORE
    reason: Legitimate downstream effect of IRF4 transcriptional activity. IL-2 is
      a direct transcriptional target of IRF4, as shown by promoter-reporter assays.
      While this is a more direct relationship than some other cytokine regulation
      annotations, it represents a specific downstream output of IRF4's core transcription
      factor activity rather than the core function itself.
    supported_by:
    - reference_id: PMID:12374808
      supporting_text: We demonstrate that stable expression of IRF-4 in Jurkat T
        cells not only leads to a strong enhancement in the synthesis of interleukin
        (IL)-2, but also enables these cells to start producing considerable amounts
        of IL-4, IL-10, and IL-13.
- term:
    id: GO:0032753
    label: positive regulation of interleukin-4 production
  evidence_type: IDA
  original_reference_id: PMID:12374808
  review:
    summary: Hu et al. (2002) showed that stable IRF4 expression in Jurkat T cells
      enabled production of IL-4. IRF4 transactivates the IL-4 promoter and binds
      a site adjacent to an NFAT element, cooperating with NFATc1.
    action: KEEP_AS_NON_CORE
    reason: Legitimate and well-supported downstream effect. IRF4 directly binds and
      activates the IL-4 promoter. This is a specific and well-characterized output
      of IRF4's transcription factor activity in the context of Th2 differentiation.
      Kept as non-core because it represents one specific target gene regulation downstream
      of the core TF activity.
    supported_by:
    - reference_id: PMID:12374808
      supporting_text: A detailed analysis of the effects of IRF-4 on the IL-4 promoter
        reveals that IRF-4 binds to a site adjacent to a functionally important NFAT
        binding element and that IRF-4 cooperates with NFATc1.
- term:
    id: GO:0042110
    label: T cell activation
  evidence_type: NAS
  original_reference_id: PMID:12374808
  review:
    summary: NAS annotation from Hu et al. (2002) for T cell activation. The paper
      discusses IRF4's role in modulating T cell cytokine production, noting that
      IRF4 deficiency impairs mature CD4+ T cell function.
    action: KEEP_AS_NON_CORE
    reason: IRF4 is important for T cell activation and function, but this is a downstream
      organismal process rather than a direct molecular activity. The NAS evidence
      code indicates this is based on statements in the paper rather than direct experimental
      demonstration in this study. T cell activation is a broad term encompassing
      many steps, and IRF4 contributes primarily through its transcriptional programs
      that enable cytokine production.
    supported_by:
    - reference_id: PMID:12374808
      supporting_text: Interferon regulatory factor (IRF)-4 is a lymphoid-restricted
        member of the interferon regulatory factor family of transcriptional regulators,
        whose deficiency leads to a profound impairment in the ability of mature CD4(+)
        T cells to produce cytokines.
- term:
    id: GO:0045622
    label: regulation of T-helper cell differentiation
  evidence_type: NAS
  original_reference_id: PMID:12374808
  review:
    summary: NAS annotation for regulation of T-helper cell differentiation based
      on Hu et al. (2002). The paper discusses how IRF4 controls T cell cytokine production,
      which is closely linked to Th cell differentiation programs.
    action: ACCEPT
    reason: IRF4 is genuinely critical for T-helper cell differentiation, including
      Th2, Th9, and Th17 lineages. While the evidence code is NAS (non-traceable author
      statement), this function is extremely well-established in subsequent literature.
      IRF4 is a master regulator of multiple Th cell differentiation programs.
    supported_by:
    - reference_id: PMID:12374808
      supporting_text: These studies thus support the notion that IRF-4 represents
        one of the lymphoid-specific components that control the ability of T lymphocytes
        to produce a distinctive array of cytokines.
- term:
    id: GO:0045893
    label: positive regulation of DNA-templated transcription
  evidence_type: IDA
  original_reference_id: PMID:12374808
  review:
    summary: IDA annotation from Hu et al. (2002) showing IRF4 positively regulates
      DNA-templated transcription. Demonstrated by transactivation of IL-2 and IL-4
      promoter-reporter constructs and enhancement of endogenous cytokine gene expression.
    action: ACCEPT
    reason: Direct experimental evidence supporting IRF4 as a positive regulator of
      transcription. This is a core biological process annotation complementing the
      MF transcription activator annotations.
    supported_by:
    - reference_id: PMID:12374808
      supporting_text: Transient transfection assays indicate that IRF-4 can transactivate
        luciferase reporter constructs driven by either the human IL-2 or the human
        IL-4 promoter.
- term:
    id: GO:1900100
    label: positive regulation of plasma cell differentiation
  evidence_type: NAS
  original_reference_id: PMID:29537367
  review:
    summary: IRF4 is essential for plasma cell differentiation. Loss-of-function variants
      in IRF4 cause combined immunodeficiency (IMD131) characterized by low immunoglobulin
      levels and low plasma cell counts (PMID:29537367, PMID:36662884, PMID:36917008).
      IRF4 cooperates with BLIMP1/XBP1 to drive the plasma cell differentiation program.
      In multiple myeloma, IRF4 is a lineage addiction factor for malignant plasma
      cells.
    action: NEW
    reason: This is a major gap in the current annotation set. Plasma cell differentiation
      is one of the best-established and most important biological functions of IRF4,
      yet it is not annotated. Human genetic evidence from IMD131 patients directly
      demonstrates IRF4's requirement for plasma cell differentiation. The Reactome
      and UniProt entries both reference IRF4's role in B cell/plasma cell biology.
    supported_by:
    - reference_id: PMID:29537367
      supporting_text: AD IRF4 deficiency can underlie WD by haploinsufficiency, with
        age-dependent incomplete penetrance.
    - reference_id: PMID:36917008
      supporting_text: Expression of the mutant IRF4 protein in control lymphoblastoid
        B cell lines reduced the expression of BLIMP-1 and XBP1 (key transcription
        factors in plasma cell differentiation).
references:
- id: GO_REF:0000002
  title: Gene Ontology annotation through association of InterPro records with GO
    terms
  findings: []
- id: GO_REF:0000024
  title: Manual transfer of experimentally-verified manual GO annotation data to orthologs
    by curator judgment of sequence similarity
  findings: []
- id: GO_REF:0000033
  title: Annotation inferences using phylogenetic trees
  findings: []
- id: GO_REF:0000043
  title: Gene Ontology annotation based on UniProtKB/Swiss-Prot keyword mapping
  findings: []
- id: GO_REF:0000044
  title: Gene Ontology annotation based on UniProtKB/Swiss-Prot Subcellular Location
    vocabulary mapping, accompanied by conservative changes to GO terms applied by
    UniProt
  findings: []
- id: GO_REF:0000052
  title: Gene Ontology annotation based on curation of immunofluorescence data
  findings: []
- id: GO_REF:0000107
  title: Automatic transfer of experimentally verified manual GO annotation data to
    orthologs using Ensembl Compara
  findings: []
- id: GO_REF:0000113
  title: Gene Ontology annotation of human sequence-specific DNA binding transcription
    factors (DbTFs) based on the TFClass database
  findings: []
- id: GO_REF:0000117
  title: Electronic Gene Ontology annotations created by ARBA machine learning models
  findings: []
- id: GO_REF:0000120
  title: Combined Automated Annotation using Multiple IEA Methods
  findings: []
- id: PMID:12374808
  title: Modulation of T cell cytokine production by interferon regulatory factor-4.
  findings:
  - statement: IRF4 is lymphoid-restricted and its deficiency impairs CD4+ T cell
      cytokine production
    supporting_text: Interferon regulatory factor (IRF)-4 is a lymphoid-restricted
      member of the interferon regulatory factor family of transcriptional regulators,
      whose deficiency leads to a profound impairment in the ability of mature CD4(+)
      T cells to produce cytokines.
  - statement: Stable IRF4 expression in Jurkat T cells enhances IL-2 and enables
      IL-4, IL-10, IL-13 production
    supporting_text: We demonstrate that stable expression of IRF-4 in Jurkat T cells
      not only leads to a strong enhancement in the synthesis of interleukin (IL)-2,
      but also enables these cells to start producing considerable amounts of IL-4,
      IL-10, and IL-13.
  - statement: IRF4 transactivates IL-2 and IL-4 promoter-reporter constructs
    supporting_text: Transient transfection assays indicate that IRF-4 can transactivate
      luciferase reporter constructs driven by either the human IL-2 or the human
      IL-4 promoter.
  - statement: IRF4 binds a site in the IL-4 promoter adjacent to an NFAT binding
      element and cooperates with NFATc1
    supporting_text: A detailed analysis of the effects of IRF-4 on the IL-4 promoter
      reveals that IRF-4 binds to a site adjacent to a functionally important NFAT
      binding element and that IRF-4 cooperates with NFATc1.
- id: PMID:19946888
  title: Defining the membrane proteome of NK cells.
  findings:
  - statement: Proteomics study of NK cell membrane fractions identified 1843 proteins
      including IRF4
    supporting_text: The remaining species were largely involved in cellular processes
      and molecular functions that could be predicted to be transiently associated
      with membranes.
  - statement: Approximately 60% of identified proteins were not predicted membrane
      proteins
    supporting_text: approximately 40% of the identified proteins were predicted as
      plausible membrane proteins.
- id: PMID:21903422
  title: Mapping a dynamic innate immunity protein interaction network regulating
    type I interferon production.
  findings:
  - statement: Large-scale interactome mapping (HI5) of innate immune signaling
    supporting_text: IKBKAP interacts with IRF4 and negatively regulates HSV-induced
      IFN production.
  - statement: IKBKAP (ELP1) interacts with IRF4 and negatively regulates HSV-induced
      IFN production
    supporting_text: IKBKAP interacts with IRF4 and negatively regulates HSV-induced
      IFN production.
  - statement: IRF4 interactions with IRAK1, TLK2, YTHDC2 detected
    supporting_text: Fifty-eight baits were associated with 260 interacting proteins
      forming a human innate immunity interactome for type I interferon (HI5) of 401
      unique interactions
- id: PMID:24995979
  title: IRF4 is a key thermogenic transcriptional partner of PGC-1α.
  findings:
  - statement: Mouse Irf4 promotes thermogenic gene expression in brown adipose tissue
    supporting_text: Here, we identify interferon regulatory factor 4 (IRF4) as a
      dominant transcriptional effector of thermogenesis. IRF4 is induced by cold
      and cAMP in adipocytes and is sufficient to promote increased thermogenic gene
      expression, energy expenditure, and cold tolerance.
- id: PMID:28473536
  title: Impact of cytosine methylation on DNA binding specificities of human transcription
    factors.
  findings:
  - statement: Systematic SELEX analysis of 542 human TFs including IRF4
    supporting_text: By analysis of 542 human TFs with methylation-sensitive SELEX
      (systematic evolution of ligands by exponential enrichment), we found that there
      are also many TFs that prefer CpG-methylated sequences.
  - statement: Provided direct biochemical evidence of IRF4 sequence-specific DNA
      binding
    supporting_text: In this work, we performed systematic analysis of DNA binding
      specificities of full-length TFs and eDBDs using unmethylated and CpG-methylated
      DNA ligands.
- id: PMID:29537367
  title: IRF4 haploinsufficiency in a family with Whipple's disease.
  findings:
  - statement: R98W variant causes loss of DNA-binding transcription activator activity
    supporting_text: We found that R98W was loss-of-function, modified the transcriptome
      of heterozygous leukocytes following Tw stimulation, and was not dominant-negative.
  - statement: RC98-99AA double mutant also loses activity
    supporting_text: IRF4 R98A-C99A, which is LOF for DNA binding (Brass et al., 1999),
      was included as a negative control.
  - statement: IRF4 haploinsufficiency causes combined immunodeficiency (IMD131)
    supporting_text: AD IRF4 deficiency can underlie WD by haploinsufficiency, with
      age-dependent incomplete penetrance.
- id: PMID:32296183
  title: A reference map of the human binary protein interactome.
  findings:
  - statement: HuRI systematic yeast two-hybrid interactome mapping
    supporting_text: Here we present a human 'all-by-all' reference interactome map
      of human binary protein interactions, or 'HuRI'.
  - statement: IRF4 interactions with GIPC2 and TSEN54 detected
    supporting_text: Here we present a human 'all-by-all' reference interactome map
      of human binary protein interactions, or 'HuRI'. With approximately 53,000 protein-protein
      interactions, HuRI has approximately four times as many such interactions as
      there are high-quality curated interactions from small-scale studies.
- id: PMID:33951726
  title: Constrained chromatin accessibility in PU.1-mutated agammaglobulinemia patients.
  findings:
  - statement: IRF4 directly interacts with PU.1 (SPI1)
    supporting_text: Consistent with intact PEST domains, all three proteins coimmunoprecipitated
      with IRF4 and IRF8 (Fig. S5 E).
  - statement: PU.1 mutations impair chromatin accessibility in B cell development
    supporting_text: Once in open chromatin, PU.1 can directly control gene expression
      by binding genetic regulatory elements and can also more broadly influence transcription
      by recruiting nonpioneers, such as interferon regulatory factors (IRFs), to
      otherwise inaccessible genomic regions (Ciau-Uitz et al., 2013; Heinz et al.,
      2013; Pongubala and Atchison, 1997; Sherwood et al., 2014).
- id: PMID:36662884
  title: A multimorphic mutation in IRF4 causes human autosomal dominant combined
    immunodeficiency.
  findings:
  - statement: T95R variant gains neomorphic DNA binding to GATA sequences
    supporting_text: IRF4T95R behaved as a gain-of-function hypermorph by binding
      to DNA with higher affinity than IRF4WT. Despite this increased affinity for
      DNA, the transcriptional activity on IRF4 canonical genes was reduced, showcasing
      a hypomorphic activity of IRF4T95R.
  - statement: Decreased activation from canonical ISRE reporter
    supporting_text: Simultaneously, IRF4T95R functions as a neomorph by binding to
      noncanonical DNA sites to alter the gene expression profile, including the transcription
      of genes exclusively induced by IRF4T95R but not by IRF4WT.
  - statement: Confirms wildtype IRF4 DNA-binding transcription activator activity
    supporting_text: Interferon regulatory factor 4 (IRF4) is a transcription factor
      (TF) and key regulator of immune cell development and function.
- id: PMID:36917008
  title: A neomorphic mutation in the interferon activation domain of IRF4 causes
    a dominant primary immunodeficiency.
  findings:
  - statement: F359L variant loses DNA-binding transcription activator activity
    supporting_text: The mutant IRF4 failed to efficiently regulate the transcriptional
      activity of interferon-stimulated response elements (ISREs).
  - statement: No effect on subcellular location (nucleus/cytoplasm)
    supporting_text: The IRF4 F359L and IRF4 WT proteins were similar with regard
      to their subcellular localization in the cytoplasm and the nucleus
  - statement: Confirms wildtype IRF4 functions as transcriptional activator in nucleus
    supporting_text: Expression of the mutant IRF4 protein in control lymphoblastoid
      B cell lines reduced the expression of BLIMP-1 and XBP1 (key transcription factors
      in plasma cell differentiation).
- id: Reactome:R-HSA-1015702
  title: Expression of IFN-induced genes
  findings: []
- id: Reactome:R-HSA-1031716
  title: Expression of IFNG-stimulated genes
  findings: []
- id: Reactome:R-HSA-6790041
  title: Expression of STAT3-upregulated cytosolic proteins
  findings: []
- id: Reactome:R-HSA-9851117
  title: NPM1-ALK- and p-STAT3-dependent IRF4 gene expression
  findings: []
- id: Reactome:R-HSA-9907145
  title: IRF4 binds the TYR promoter
  findings: []
- id: Reactome:R-HSA-9907147
  title: MITF-M-dependent IRF4 gene expression
  findings: []
core_functions:
- molecular_function:
    id: GO:0001228
    label: DNA-binding transcription activator activity, RNA polymerase II-specific
  description: IRF4 functions as a sequence-specific DNA-binding transcriptional activator.
    It binds ISRE (interferon-stimulated response element) motifs and composite elements
    (EICE with PU.1/SPI-B, AICE with BATF/JUN) to activate transcription of target
    genes. The N-terminal tryptophan pentad repeat domain (aa 21-129) mediates DNA
    binding, while the C-terminal IRF-associated domain (IAD) mediates heterodimerization
    with partner TFs. IRF4 has intrinsically weak solo DNA-binding activity and acquires
    target gene specificity through its partner TFs.
  supported_by:
  - reference_id: PMID:12374808
    supporting_text: Transient transfection assays indicate that IRF-4 can transactivate
      luciferase reporter constructs driven by either the human IL-2 or the human
      IL-4 promoter.
  directly_involved_in:
  - id: GO:0006357
    label: regulation of transcription by RNA polymerase II
  - id: GO:0045944
    label: positive regulation of transcription by RNA polymerase II
  - id: GO:0045622
    label: regulation of T-helper cell differentiation
  locations:
  - id: GO:0005634
    label: nucleus
  - id: GO:0000785
    label: chromatin
- molecular_function:
    id: GO:0000981
    label: DNA-binding transcription factor activity, RNA polymerase II-specific
  description: IRF4 regulates Pol II-dependent transcription of target genes involved
    in immune cell differentiation and function, including cytokine genes (IL-2, IL-4,
    IL-10, IL-13, IL-17), immunoglobulin genes, and differentiation program genes.
    It primarily functions as a transcriptional activator, though context-dependent
    repressive roles have been described. IRF4 cooperates with PU.1/SPI-B at EICE
    elements in B cells and with BATF/JUN at AICE elements in T cells.
  directly_involved_in:
  - id: GO:0045893
    label: positive regulation of DNA-templated transcription
  - id: GO:0002376
    label: immune system process
  locations:
  - id: GO:0005634
    label: nucleus
  - id: GO:0005654
    label: nucleoplasm

Gene Description

Existing Annotations Review

Core Functions

References

Deep Research

Falcon

Citations

📄 View Raw YAML